MXPA99008012A

MXPA99008012A - Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists

Info

Publication number: MXPA99008012A
Application number: MXPA/A/1999/008012A
Authority: MX
Inventors: M Devries Keith; Mckowan Welch Willard Jr
Original assignee: Pfizer Products Inc
Priority date: 1997-02-28
Filing date: 1999-08-30
Publication date: 2000-01-01

Abstract

Atropisomers of formula (Ia), wherein R2 is an optionally substituted aryl or heteroaryl, R5 is alkyl, halo, CF3, alkoxy or alkylthio, R6, R7 and R8 are hydrogen or halo, and R3 is hydrogen, halo, CN, NO2, CF3, alkyl or alkoxy, are useful as AMPA receptor antagonists, particularly in the treatment of neurodegenerative and CNS-trauma related conditions.

Description

ATROPISOMEROS DE 3-ARIL-4 (3H) -QUINAZOLINONES BACKGROUND OF THE INVENTION The present invention relates to atropisomers of 3-aryl-4 (3H) -quinazolinones of the formula I, described below, to their pharmaceutically acceptable salts and to pharmaceutical compositions and methods for the treatment of neurodegenerative and CNS trauma related conditions. Atropisomers are isomeric compounds that are chiral, that is, each isomer can not be superimposed on its mirror image and the isomers, once separated, rotate the polarized light in equal amounts but in opposite directions. Atropisomers are distinguished from enantiomers in that atropisomers do not possess a single asymmetric atom. Atropisomers are conformational isomers that appear when the rotation around a single bond of the molecule is impeded or greatly diminished as a result of steric interactions with other parts of the molecule and the substituents of the two ends of the single bond are asymmetric. A detailed list of atropisomers can be found in Jerry March, Advanced Qrganic Chemistry, 101-102 (4th ed., 1992) and in Oki, Top. Stereochem., 14, 1-81 (1983). The compounds of the invention provide the first evidence that quinazolinone atropisomers can be separated and that the separate isomers possess different AMPA receptor antagonist activities. Colebrook and others. Dog. J. Chem., 53. 3431-4, (1975), observed an impeded rotation around C-N bonds of aryl groups in the quinazolinones, but did not separate or suggest that rotational isomers could be separated. U.S. Patent Application 60 / 017,738, filed May 15, 1996 and entitled "Novel 2,3-Disubstituted-4- (3H) -Quinazolinones" ("New 4- (3H) -Quinazolinones 2,3 -Replaced ") and U.S. Patent Application 60 / 017,737, filed May 15, 1996 and entitled" Novel 2,3-DisuPstituted- (5.6) -Heteroarylfused-Pyrimidin-4-ones "(" New P "). Rimidin-4-ones (5,6) - 2,3-Disubstituted Heteroaryl-Deconstituted "), the two applications being incorporated herein in their entirety by reference, refer to racemic quinazolines and pyrimidinones. The inventors of the present invention have discovered that, surprisingly, a quinazolinone isomer, defined by the spatial positions of substituents due to steric interactions, possesses all the antagonist activity of the AMPA receptor. AMPA receptors are subspecies of glutamate receptors, identified by their ability to bind to a-amino-3-h id hydroxy-5-methyl-4-oxazole propionic acid (AMPA), which are involved as neurotransmitter receptors. post-synaptic for excitatory amino acids. The role of excitatory amino acids, such as glutamic acid and aspartic acid, as predominant mediators of excitatory synaptic transmission in the central nervous system is well established. Watkins and Evans, Ann. Rev. Pharmacol. Toxico!., 21, 165 (1981); Monaghan, Bridges and Cotman, Ann. Rev. Pharmacol. Toxico!., 29, 365 (1989); Watkins, Krogsgaard-Larsen and Honore, Trans. Pharm. sci., 11, 25 (1990). These amino acids function in synaptic transmission mainly through excitatory amino acid receptors. These amino acids also participate in a variety of different physiological processes, such as motor control, respiration, cardiovascular regulation, sensory perception and cognition. Excitatory amino acid receptors are classified into two general types. The receptors that attach directly to the cellular membrane of the neurons for the opening of cation channels are called "ionotropic". This type of receptor has been subdivided into at least three subtypes that are defined by the depolarizing actions of the selective agonists N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and cainic acid (KA). The second general type is the G protein or "metabotropic" receptor of excitatory amino acids attached to second messengers. This second type, when activated by the agonists quisqualate, ibotenate or trans-1-aminocyclopentane-1,3-dicarboxylic acid, produces an increase in the hydrolysis of phosphoinositide in the post-synaptic cell. It seems that the two types of receptors not only mediate normal synaptic transmission along the excitatory pathways, but also participate in the modification of the synaptic connection during development and change the efficiency of synaptic transmission throughout the lifetime. Schoepp, Bockaert and Sladeczek. Trends in Pharmacol. Sci., 11, 508 (1990); McDonald and Johnson, Brain Research Reviews, 15, 41 (1990). Excessive or inappropriate stimulation of excitatory amino acid receptors results in injury or loss of neuronal cells through a mechanism known as excitotoxicity. It has been suggested that this process mediates neuronal degeneration in a variety of conditions. The medical consequences of such neuronal degeneration make the relief of these degenerative neurological processes an important therapeutic goal. The excitotoxicity of excitatory amino acids has been implicated in the pathophysiology of several neurological disorders. This excitotoxicity has been implicated in the pathophysiology of acute and chronic neurodegenerative conditions, including subsequent brain deficits or resulting from cardiac bypass surgery and grafts, stroke, cerebral ischemia, spinal cord trauma, head trauma, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, AIDS-induced dementia, perinatal hypoxia, hypoxia (such as conditions caused by strangulation, surgery, smoke inhalation, asphyxia, drowning, airway obstruction, electrocution, or drug overdose or alcohol), cardiac arrest, hypoglycaemic neuronal injury, ocular injury, retinopathy and Parkinson's disease and drug-induced dioptatic. Neuromodulation also requires other neurological conditions caused by glutamate dysfunction. These other neurological conditions include muscle spasms, migraines, urinary incontinence, psychosis, withdrawal syndrome (such as that produced by alcoholism and drug addiction, including opiate addiction, cocaine and nicotine), opioid tolerance, anxiety, emesis , cerebral edema, chronic pain, seizures, retinal neuropathy, tinnitus and tardive dyskinesia. It is believed that the use of a neuroprotective agent, such as an AMPA receptor antagonist, is useful in treating these disorders and / or in reducing the dimension of the neurological lesions associated with these disorders. Antagonists of excitatory amino acid receptors (EAA) are also useful as analgesic agents. Several studies have shown that AMPA receptor antagonists are neuroprotective in models of focal and global ischemia. The competitive antagonist of the AMPA receptor NBQX (2,3-dihydroxy-6-nitrp-7-sulfamoylbenzo [f-] quinoxaline) has been reported to be effective in the prevention of global and focal ischemic lesions. Sheardown et al., Science, 247, 571 (1900); Buchan et al., Neuroreport, 2, 473 (1991); LePeillet et al., Brain Research, 571, 115 (1992). It has been shown that non-competitive AMPA receptor antagonists GKYI 52466 are effective neuroprotective agents in rat global ischemia models. LaPeillet and. others, Brain Research, 571, 115 (1992). These studies strongly suggest that the delayed neuronal degeneration of cerebral ischemia involves an excitotoxicity of glutamate mediated at least in part by the activation of the AMPA receptor. Thus, AMPA receptor antagonists may be useful as neuroprotective agents and to improve the neurological results of cerebral ischemia in humans.

BRIEF DESCRIPTION OF THE INVENTION The present invention relates to an atropisomer of the formula wherein R2 is a phenyl group of the formula Ph2 or a five or six membered heterocycle; where said 6-membered heterocycle has the formula wherein "N" is nitrogen; wherein said positions of the ring "K", "L" and "M" can be independently selected from carbon and nitrogen, with the proviso that i) only one of "K", "L" and "M" can be nitrogen and ) when "K", "L" or "M" is nitrogen, then the respective R15, R16 or R17 is absent; where said five-membered heterocycle has the formula wherein said "T" is -CH-, N, NH, O or S; wherein said positions of the ring "P" and "Q" can be independently selected from carbon, nitrogen, oxygen and sulfur; with the proviso that (i) only one of "P", "Q" or "T" can be oxygen, NH or sulfur; (I) at least one of "P", "Q" or "T" must be a heteroatom; and (iii) when "P" or "Q" is oxygen or sulfur, then the respective R15 or R16 is absent. where said Ph2 is a group of the formula R3 is hydrogen, halo, -CN, -NO2, CF3, (C? -C6) alkyl or alkoxy (C? -C6); R5 is alkyl (CrC6), halo, CF3, (C6) alkoxy or alkylthiol (C6C6); R6 is hydrogen or halo; R7 is hydrogen or halo; R8 is hydrogen or halo; R9 is hydrogen, halo, CF3, alkyl (Ci-Cß) optionally substituted with one to three halogen atoms, (C -? - C6) alkoxy optionally substituted with one to three halogen atoms, alkylthiol (C? -C6), amino- (CH2) S-, alkyl (C6C6) -NH- (CH2) S-, dialkyl (C1-C6) -N- (CH2) S-, cycloalkyl (C3-C7) -NH- (CH2 ) S-, H2N- (C = O) - (CH2) s-, alkyl (C? -C6) -NH- (C = O) - (CH2) s-, dialkyl (C1-C6) -N- ( C = O) - (CH2) s-, cycloalkyl (C3-C7) -NH- (C = O) - (CH2) s-, R13O- (CH2) s-, R130- (C = 0) - (CH2 ) s-, H- (C = 0) -NH- (CH2) s-, (C6) alkyl- (C1-C6) alkyl- (C = 0) -N- (CH2) s-, H (C = 0) -N- (CH2) s-, II alkyl (CrC6) alkyl (d-C6) alkyl (C? -C6) alkyl (C6) H- (C = 0) - (CH2) s-, alkyl (C C6) - (C = 0) -, hydroxy, hydroxy-alkyl (CrCe), alkyl (C? -C6) -0-alkyl (C? -C6) and -CN; R10 is hydrogen or halo; R11 and R14 are independently selected from hydrogen, halo, CF3, alkyl (CrC6) optionally substituted with one to three halogen atoms, alkoxy (Ci-Cß) optionally substituted with one to three halogen atoms, alkylthiol (C? - C6), amino- (CH2) p-, alkyl (C? -C6) -NH_ (CH2) P-, dialkyl (CrC6) -N- (CH2) p-, cycloalkyl (C3-C7) -NH- (CH2 ) P-, amino-aikyl (CrC 6) -NH- (CH 2) p-, alkyl (C Ce) -NH-alkyl (CrC 6) -NH- (CH 2) P-, dialkyl (C C 6) -N-alkyl ( CrC6) -NH- (CH2) p-, dialkyl (C6C) -N-alkyl (CrC6) -N- (CH2) p-, H2N- (C = 0) - I alkyl (CrC6) (CH2) P- , alkyl (CrC6) -HN- (C = O) - (CH2) p-, dialkyl (CrC6) -N- (C = OHCH2) p-, cycloalkyl (C3-C7) -NH- (C = 0) - (CH2) p-, R130- (CH2) P-, R130- (CH2) p-, H (C = 0) -O-, H4-0-alkyl (C6), H (C = 0) -NH - (CH2) p-, alkyl (CrC6) - (C = 0) -NH- (CH2) P-, -CHO, H- (C = 0) - (CH2) p-, alkyl (CrC6) - (C = 0) - (CH2) p-, alkyl (C6) - (C = O) -N- (CH2) P-, H (C = O) -N- (CH2) p-, HO-alkyl (C C6) - II alkyl (CrC6) alkyl (CrC6) N- (CH2) P-, alkyl (CrC6) - (C = 0) -0- (CH2) p-, amino-alkyl or (C aikyl (CrC6) C6) - (C = 0) -0- (CH2) p-, alkyl (CrC6) -NH-alkyl (CrC6) - (C = O) -O- (CH2) P-, dialkyl (C C6) -N-alkyl (CrC6) - (C = O) -0- (CH2) p-, amine-alkyl (d-C6) -0- (C = O) - (CH2) p-, alkyl (CrC6) -NH-aikyl dialkyl (CrC6) -N-alkyl (CrC6) -0- (C = 0) - (CH2) p-, hydroxy, hydroxy-alkyl (C6) -, hydroxy-alkyl (Cr6) -NH- (CH2) p-, alkyl (CrC6) -0- alkyl (CrC6) -CN, piperidine- (CH2) P-, pyrrolidine- (CH2) p-, and 3-pyrroline- (CH2) p-, wherein said radical piperidine, pyrrolidine and 3-pyrroline of said groups piperidine- (CH2) p-, pyrrolidine- (CH2) p-, and 3-pyrroline- (CH2) p-, may optionally be substituted in any of the ring carbon atoms capable of supporting an additional bond, preferably with zero to two substituents, a substituent being independently selected from halo, CF3, alkyl (CrCβ) optionally substituted with one to three halogen atoms, alkoxy (CrCe) optionally substituted with one to three halogen atoms, alkylthiol (d-Cß), amino (CH2) P-, alkyl (CrC6) -NH- (CH2) P-, dialkyl (d-Ce) -N- (CH2) P-, cycloalkyl (C3-C7) NH - (CH2) P-, amino-alkyl (CrC6) -NH- (CH2) p-, alkyl (CrC6) -NH-alkyl (CrC6) -NH- (CH2) p-, alkyl (CrC6) -NH-alkyl (Cr C6) -NH- (CH2) P-dialkyl (CrC6) -N-alkyl (CrC6) -NH- (CH2) p-, alkyl (CrC6) -O-alkyl (CrC6), dialquiio (CrC6) -N - alkyl (CrC6) -N- (CH2) p-, H2N- (C = 0) - alkyl (CrC6) alkyl (CrC6) (CrC6) -HN- (C = OHCH2) p-, dialkyl (CrC6) -N - (C = O) - (CH2) p-) cycloalkyl (C3-C7) -NH- (C = OHCH2) P-, R130- (CH2) p-, R130- (C = O) - (CH2) P -, H (O =) - 0-, H (O =) - O-alkyl (CrC6) -, H (0 =) - NH- (CH2) p-, alkyl (CrC6) - (C = 0) - NH- (CH2) P-, -CHO, H- (C = O) - (CH2) P-, alkyl (CrC6) - (C = O) - alkyl (d-Cß) - (C = 0) - N - (CH2) P-, H (C = 0) -N- (CH2) P-, HO-alkyl (CrC6) - II alkyl (CrC6) alkyl (CrCß) N- (CH2) P-, alkyl (CrC5) - (C = 0) -0-NH- (CH2) p-, aminoalkyl | alkyl (CrC6) (CrC6) - (C = O) -O- (CH2) p-, alkyl (CrCß) -NH-alkyl (CrC6) - (C = O) -O- (CH2) p-, dialkyl ( CrC6) -N-alkyl (CrC6) - (C = O) -O- (CH2) p-, hydroxy, hydroxy-alkyl (Ci- R13 is hydrogen, alkyl (CrC6), alkyl (CrC6) - (C = 0 ) -, alkyl (CrC6) -0- (C = O) -, alkyl (CrC6) -NH-alkyl (CrC6), dialkyl (CrC6) -N-alkyl (CrC6) -, alkyl (CrC6) -NH- ( C = 0) - or dialkyl (CrC6) -N- (C = 0) -; R15 is hydrogen, -CN, (C? -C6) alkyl, halo, CF3, -CHO or (C6C) alkoxy; R16 is hydrogen, -CN, (C6C) alkyl, halo, CF3, -CHO or (C6C) alkoxy; R17 is hydrogen, -CN, alkyl (CrC6), amino-alkyl (CrC6), alkyl (CrC6) -NH-alkyl (CrC6), dialkyl (CrCß) -N- alkyl (CrCß) -, halo, CF3, -CHO or alkoxy (CrCß); n is an integer from zero to 3; each p is, independently, an integer from zero to 4. s is an integer from zero to 4; where the dashed link represents an optional double bond; and pharmaceutically acceptable salts of such compounds. The present invention also relates to pharmaceutically acceptable acid addition salts of the compounds of formula la. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned basic compounds of this invention, are those which form non-toxic acid addition salts, ie, salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydrate, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p toluenesulfonate and pamoate [ie, 1, r-methylene-bis- (2-hydroxy-3-naphthoate)].

The invention also relates to the addition salts of bases of the formula la. The chemical bases that can be used as reagents for preparing pharmaceutically acceptable base salts of the compounds of formula which are acidic in nature, are those which form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to, those derived from pharmacologically acceptable cations such as alkali metal cations, (e.g., potassium and sodium) and alkaline earth metal cations (e.g. calcium and magnesium), addition salts of water-soluble ammonium or amine, such as N-methylglucamine (meglumine), the lower alkanolammonium salts and other salts of pharmaceutically acceptable organic amine bases. Preferred compounds of formula la are those in which R3 is hydrogen, halo or alkyl (CrC6). Preferred compounds of formula la are those in which one of R5, R6, R7 or R8 is fluoro, bromo, chloro, methyl or trifluoromethyl, preferably R5 is fluoro, bromo, chloro, methyl or trifluoromethyl. The most preferred compounds of formula la, are those in which R5 is chloro or methyl. Preferred compounds of the formula are those in which R2 is Ph2, those in which R9 is fluoro, chloro, -CN or hydroxy; or R11 is -CHO, chloro, fluoro, methyl, alkyl (CrC6) -NH- (CH2) p-, dialkyl (CrC6) -N- (CH2) p- or cyano.

The most preferred compounds of the formula wherein R 2 is Ph 2, are those in which R 9 is fluoro or -CN; or R11 is methyl, alkyl (CrC6) -NH- (CH2) P-, dialkyl (CrC6) -N- (CH2) P- or cyano. Preferred compounds of the formula wherein R 2 is heteroaryl, are those wherein said heteroaryl is optionally substituted six-membered heterocycle wherein "K", "L" and "M" are carbons (i.e., pyridin-2) -yl) or "K" and "L" are carbon and "M" is nitrogen (ie, pyrimidin-2-yl), or said heteroaryl is an optionally substituted five-membered heterocycle wherein "T" is nitrogen, "P" is sulfur and "Q" is carbon (ie, 1,3-thiazol-4-yl), "T" is nitrogen or sulfur, "Q" is nitrogen or sulfur and "P" is carbon (i.e. , 1,3-thiazol-2-yl) or "T" is oxygen and "P" and "Q" are each a carbon (ie, fur-2-yl). Preferred compounds of the formula wherein R 2 is an optionally substituted six-membered heterocycle, wherein "K", "L" and "M" are carbons (ie, pyridin-2-yl), are those in the that R14 is hydrogen, -CHO, chloro, fluoro, methyl, alkyl (CrCβ) -NH- (CH 2) P-, dialkyl (CrC 6) -N- (CH 2) p- or cyano, R 17 is hydrogen, -CHO, chloro , fluro, methyl, alkyl (CrC6) -NH-alkyl (CrC6), dialkyl (CrC6) -N-alkyl (CrC6) or cyano; or R15 or R16 are, independently, hydrogen, -CHO, chloro, fluoro, methyl or cyano. The most preferred compounds of the formula wherein R 2 is an optionally substituted six-membered heterocycle, wherein "K", "L" and "M" are carbons (ie, pyridin-2-yl), are those in which wherein R14 is hydrogen, -CHO, methyl, alkyl (CrC6) -NH- (CH2) p-, dialkyl (C6) -N- (CH2) p- or cyano.

Preferred compounds of the formula wherein R 2 is an optionally substituted five-membered heterocycle wherein "T" is nitrogen, "P" is sulfur and "Q" is carbon (i.e., 1,3-thiazole-4) ilo) are those in which R14, R15 or R16 are each, independently, hydrogen, chloro, fluoro, methyl or cyano. Preferred compounds of the formula wherein R 2 is an optionally substituted five-membered heterocycium wherein "T" is nitrogen or sulfur, "Q" is sulfur or nitrogen and "P" is carbon (i.e., 1, 3- thiazol-2-yl), are those in which R 14 or R 15 are independently hydrogen, chloro, fluoro, methyl or cyano. Examples of the preferred specific compounds of the invention include: (S) -3- (2-chloro-phenyl) -2- [2- (5-diethylaminomethyl-2-fluoro-phenyl) -vinyl] -6-fluro- 3 H -quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -2- [2- (6-diethylaminomethyl-pyridin-2-yl) -vinyl] -6-fluro-3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -2- [2- (4-diethylaminomethyl-pyridin-2-yl) -vinyl] -6-fluoro-3 H -quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -2- [2- (6-ethylaminomethyl-pyridin-2-yl) -vinyl] -6-fluoro-3 H -quinazolin-4-one; (S) -3- (2-Bromo-phenyl) -2- [2- (6-diethylaminomethyl-pyridin-2-yl) -vinyl] -6-fluoro-3 H -quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -6-fluoro-2- [2- (6-methoxymethyl-pyridin-2-yl) -vinyl] -3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyi) -6-fluoro-2- [2- (4-methyl-pyrimidine-2-yl) -v] nyl] -3H-quinazolin-4 -one; (S) -3- (2-chloro-phenyl) -6-fluoro-2-. { 2- [6- (isopropylamino-methyl) -pyridin-2-yl] -ethyl} -3H-quinazolin-4-one; and (S) -6-fluoro-2- [2- (2-methyl-thiazol-4-yl) vinyl] -3- (2-methyl-phenyl) -3H-quinazolin-4-one Other specific compounds of the invention include: (S) -3- (2-chloro-phenyl) -6-fluoro-2- [2- (2-methyl-thiazol-4-ii) -vinyl] -3H-quinazolin-4-one; (S) -3- (2-Dimethylaminomethyl-thiazol-4-yl) -vinyl] -6-fluoro-3- (2-fluoro-phenyl) -3H-quinazolin-4-one; (s) -3- (2-Bromo-phenyl) -6-fluoro-2- [2- (2-methyl-thiazol-4-yl) -vinyl] -3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -2- [2- (2-methyl-thiazol-4-yl) -vinyl] -3H-quinazolin-4-one; (S) -3- (2-chloro-phenyl) -6-fluoro-2- (2-pyridin-2-yl-vinyl) -3H-quinazoln-4-one; (S) -3- (2-Bromo-phenyl) -2- (2-pyridin-2-yl-vinyl) -3H-quinazolin-4-one; (S) -6-chloro-2- (2-pyridin-2-yl-vinyl) -3-o-tolyl-3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -2- [2- (6-methyl-pyridin-2-yl) -vinyl] -3H-quinazolin-4-one; (S) -6-chloro-2- [2- (6-methyl-pyridin-2-yl) -v] nyl] -3-o-tolyl-3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -6-fluoro-2- (2-pyridin-2-yl-ethyl) -3H-quinazolin-4-one; (S) -6-. { 2- [3- (2-Chloro-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -vinyl} -pyridine-2-carbaldehyde; (S) -3- (2-Chloro-phenyl) -6-fluoro-2- [2- (6-methylaminomethyl-pyridin-2-yl) -vinyl] -3H-quinazolin-4-one; (S) -N- (6- { 2- [3- (2-Chloro-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -vinyl}. -pyridin-2-ylmethyl) -N-methyl-acetamide; (S) -6-. { 2- [3- (2-Chloro-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -vinyl} -pyridine-2-carbonitrile; (S) -3- (2-fluro-phenyl) -2- (2-pyridin-2-yl-vinyl) -3H-quinazolin-4-one; (S) -3- (2-Bromo-phenyl) -6-fluoro-2- (2-pyridin-2-yl-vinyl) -3H-quinazolin-4-one; (S) -3- (4-Bromo-2-chloro-phenyl) -6-fluoro-2- (2-pyridin-2-yl-vinyl) -3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -2- [2- (6-d.ethylaminomethyl-pyridin-2-yl) -vinyl] -3H-quinazolin-4-one; (S) -N- (6- { 2- [3- (2-Chloro-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -vinyl. -pyridin-2-ylmethyl) -N-ethyl-acetamide; (S) -3- (2-Chloro-phenyl) -6-fluoro-2- [2- (6-fluoromethyl-pyridin-2-yl) -v -nii] -3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -6-fluoro-2- [2- (6-pyrrolidin-1-ylmethyl-pyridin-2-yl) -ethyl] -3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -2- [2- (6-. {[[Ethyl- (2-hydroxy-ethyl) -amino] -methyl] -pyridin-2-yl) -vínl] -6-fluoro-3H-quinazolin-4-one; (S) -3- (2-chloro-phenyl) -6-fluoro-2-. { 2- [6- (isopropylamino-methyl) -pyridin-2-yl] -vinyl} -3H-quinazolin-4-one; (S) -3- (2-chloro-phenyl) -6-fluoro-2-. { 2- [6- (2-methyl-piperidin-1-ylmethyl) -pyridin-2-yl-vinyl} -3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -2- [2- (6-ethoxymethyl-pyridin-2-yl) -vinyl] -6-fluoro-3 H -quinazolin-4-one; (S) -3- (2-chloro-phenyl) -2-. { 2- [6- (2,5-Dihydro-pyrrol-1-ylmethyl) -pyridin-1-yl] -vinyl} -6-fluoro-3H-quinazolin-4-one; (S) -3- (2-chloro-phenyl) -6-fluoro-2-. { 2- [6- (4-methyl-piperidin-1-ylmethyl) -piperidin-2-yl] -vinyl} -3H-quinazolin-4-one; (S) -6-bromo-2- [2- (6-methyl-pyridin-2-yl) -vin] -1 -3-o-tolyl-3H-quinazolin-4-one; (S) -6-bromo-2- (2-pyridin-2-yl-vinyl) -3-o-tolyl-3H-quinazolin-4-one; (S) -6-fluoro-3- (2-fluoro-phenyl) -2- (2-pyridin-2-yl-vinyl) -3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -6-methyl-2- (2-pyridin-2-yl-vinyl) -3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -2- [2- (6-dimethylaminomethyl-pyridin-2-yl) -vinyl] -6-fluoro-3 H -quinazolin-4-one; (S) -6-fluoro-3- (2-fluoro-phenyl) -2- [2- (6-methyl-pyridin-2-yl) -vinyl] -3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -2- [2- (6-. {[[(2-dimethylamino-ethyl) -methyl-amino] -methyl} -pyridin-2- il) -vinyl] -6-fluoro-3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -6-fluoro-2- [2- (6-hydroxymethyl-pyridin-2-yl) -v] nyl] - 3 H -quinazolin-4-one; 6- { 2- [3- (2-Chloro-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -vinyl} -pyridine-2-methyl ester of (S) -acetic acid; (S) -6-. { 2- [3- (2-bromo-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -vinyl} -pyridine-2-carbaldehyde; (S) -3- (2-Bromo-phenyl) -2- [2- (6-diethylaminomethyl-pyridin-2-yl) -vinyl] -3H-quinazolin-4-one; 6- { 2- [3- (2-bromo-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -vinyl} -pyridin-2-methyl ester of (S) -acetic acid; 6- { 2- [3- (2-chloro-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -vinyl} - (S) -diethylamino-acetic acid-pyridin-2-ylmethyl ester; (S) -3- (2-Chloro-phenyl) -2- [2- (6-difluoromethyl-pyridin-2-yl) -vinyl] -6-fluoro-3 H -quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -6-fluoro-2- [2- (6-methoxy-pyridin-2-yl) -vinyl] -3H-quinazolin-4-one; (S) -2-. { 2- [3- (2-chloro-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -vinyl} -6-methyl-nichotinonitrile; (S) -2-. { 2- [3- (2-chloro-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -ethyl} -6-methyl-nicotrinonetriol; (S) -3- (2-Chloro-phenyl) -6-fluoro-2- (2-pyrimidine-2-yl-ethyl) -3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -2- [2- (4,6-dimethyl-pyrimidine-2-yl) -v] nyl] -6-fluoro-3 H -quinazolin-4-one; (S) -2-. { 2- [3- (2-chloro-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -vinyl} -nicotinonitrile; (S) -3- (2-Chloro-phenyl) -6-fluoro-2- (2-. {6 - [(3-methyl-butylamino) -methyl] -pyridin-2-yl) -3H-quinazolin -4-one; (S) -2-. { 2- [3- (2-chloro-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -ethyl} -nicotinonitrile; (S) -2- [2- (6-Chloro-4-oxo-3-o-tolol-3,4-dihydro-quinazolin-2-yl) -vinyl] -benzonitrile; (S) -2-. { 2- [3- (2-Chloro-phenyl) -6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl] -vinyl} -4-methyl-benzonitrile; (S) -3- (2-Bromo-phenyl) -6-fluoro-2- [2- (6-hydroxymethyl-pyridin-2-yl) -vinyl] -3H-quinazolin-4-one; and (S) -3- (2-Chloro-phenyl) -6-fluoro-2- [2- (6-? rrolidin-1-ylmethyl-pyridin-2-yl) -vinyl-3H-quinazolin- 4-one. This invention also relates to a pharmaceutical composition for treating or preventing a condition selected from among subsequent brain deficits or resulting from cardiac bypass surgery and grafts, stroke, cerebral ischemia, spinal cord trauma, head trauma, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, apilepsy, AIDS-induced dementia, perinatal hypoxia, hypoxia (such as conditions caused by strangulation, surgery, smoke inhalation, asphyxia, drowning, airway obstruction, electrocution, or drug overdose or of alcohol), cardiac arrest, hypoglycemic neuronal injury, tolerance to opiates, withdrawal syndrome (such as that produced by alcoholism and by addition to drugs, including addition to opiates, cocaine and nicotine), idiopathic Parkinson's disease and induced by drugs or cerebral edema; muscle spasms, migraines, urinary incontinence, psychosis, seizures, chronic or acute pain, ocular lesions, retinopathy, retinal neuropathy, tinnitus, anxiety, emesis and tardive dyskinesia, in a mammal, comprising an amount of a compound of formula effective for treat or prevent such a condition, and a pharmaceutically acceptable vehicle. This invention also relates to a method for treating or preventing a condition selected from among subsequent brain deficits or resulting from cardiac bypass surgery and grafts, stroke, cerebral ischemia, spinal cord trauma, head trauma, Alzheimer's disease, Korea of Huntington, amyotrophic lateral sclerosis, epilepsy, AIDS-induced dementia, perinatal hypoxia, hypoxia (such as conditions caused by strangulation, surgery, inhalation of smoke, suffocation, drowning, airway obstruction, electrocution or drug overdose or of alcohol), cardiac arrest, hypoglycaemic neuronal injury, opioid tolerance, withdrawal syndrome (such as that produced by alcoholism and by addition to drugs, including addition to opiates, cocaine and nicotine), idiopathic Parkinson's disease and drug-induced or cerebral edema; muscle spasms, migraines, urinary incontinence, psychosis, chronic or acute pain convulsions, ocular lesions, retinopathy, retinal neuropathy, tinnitus, anxiety, emesis and tardive dyskinesia, in a mammal, which comprises administering to a mammal in need of such treatment or prevention , an amount of a compound of formula effective in the treatment or prevention of such a condition. This invention also relates to a pharmaceutical composition for treating or preventing a condition selected from among subsequent brain deficits or resulting from cardiac bypass surgery and grafts, stroke, cerebral ischemia, spinal cord trauma, head trauma, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, dementia induced by AIDS, perinatal hypoxia, hypoxia (such as conditions caused by strangulation, surgery, smoke inhalation, asphyxia, drowning, airway obstruction, drug or alcohol overdose or overdose), cardiac arrest, hypoglycaemic neuronal injury, opioid tolerance , withdrawal syndrome (such as that produced by alcoholism and by addition to drugs, including addition to opiates, cocaine and nicotine), idiopathic and drug-induced Parkinson's disease or cerebral edema; muscle spasms, migraines, urinary incontinence, psychosis, seizures, chronic or acute pain, ocular lesions, retinopathy, retinal neuropathy, tinnitus, anxiety, emesis and tardive dyskinesia, in a mammal, comprising an effective amount to antagonize the AMPA receptor of a compound of formula IA and a pharmaceutically acceptable carrier. This invention also relates to a method for treating or preventing a condition selected from among subsequent brain deficits or resulting from cardiac bypass surgery and grafts, stroke, cerebral ischemia, spinal cord trauma, head trauma, Alzheimer's disease, chorea of Huntington, amyotrophic lateral sclerosis, epilepsy, AIDS-induced dementia, perinatal hypoxia, hypoxia (such as conditions caused by strangulation, surgery, inhalation of smoke, suffocation, drowning, airway obstruction, electrocution or drug overdose or of alcohol), for cardiac, hypoglycemic neuronal injury, tolerance to opiates, withdrawal syndrome (such as that produced by alcoholism and by addition to drugs, including addition to opiates, cocaine and nicotine), idiopathic and drug-induced Parkinson's disease or cerebral edema; muscle spasms, migraines, urinary incontinence, psychosis, seizures, chronic or acute pain, ocular lesions, retinopathy, retinal neuropathy, tinnitus, anxiety, emesis and tardive dyskinesia, in a mammal, which comprises administering to a mammal that requires such treatment or prevention , an amount effective to antagonize the AMPA receptor of a compound of formula la.

The compounds of this invention include all stereoisomers and all optical isomers of the compounds of the formula la (for example, the R and S enantiomers), as well as racemic, diastereomeric mixtures and other mixtures of such isomers. The compounds of this invention may contain double bonds similar to those of olefins. When such bonds are present the compounds of the invention exist in the cis and trans configurations and as a mixture thereof. Unless otherwise indicated, the alkyl groups mentioned herein, as well as the alkyl radicals of other groups mentioned herein (e.g., alkoxy), may be linear or branched and may also be cyclic (e.g., cyclopropyl) , cyclobutyl, cyclopentyl or cyclohexyl) or can be linear or branched and contain cyclic radicals. Unless otherwise indicated, halo or halogen refers to fluoro, bromo, chloro or iodo. The thick lines of the formulas la and Ib, shown below, indicate that the bold atoms and the groups attached to them are sterically restricted, so that they exist orthogonally above the plane of the quinazolinone ring or orthogonally below the plane. of the quinazolinone ring. This steric restriction is due to a rotational energy barrier created by a substituent R5 which prevents free rotation around the single bond connecting the quinazolinone ring with the phenyl-containing ring (R5, R6, R7, R8). In the compounds of the formula la, the groups R5 and R6 are sterically restricted such that they exist orthogonally above the plane of the quinazolinone ring when the ring is with the vinyl group to the right of the quinazolinone ring. The compounds of formula la are denoted by the stereochemistry (S). In the compounds of formula Ib, the mirror image of the compounds of the formula shown below, the groups R5 and R6 are sterically restricted, so that they exist orthogonally above the plane of the quinazolinone ring when the vinyl group is to the left of the quinazolinone ring. The compounds of the formula Ib are denoted by the stereochemistry (R). The compounds of formula possess substantially all of the AMPA receptor antagonist activity, while the compounds of formula Ib essentially lack the antagonist activity of the AMPA receptor.

DETAILED DESCRIPTION OF THE INVENTION The compounds of the formula I can be prepared according to the procedures of scheme 1. In the reaction scheme and in the discussion that follows, K, L, M, P, Q, T, R2, R5, R6, R7, R8 , R9, R10, R11, R12, R13, R14, R15, R16, R17, Ph2, n, m and p, unless otherwise indicated, are as defined above for the formula la.

SCHEME 1 SCHEME 2 V vi Vil SCHEME 3 Scheme 1 refers to the preparation of compounds of formula la or Ib, from compounds of formula V. Compounds of formula V are commercially available or can be prepared by methods well known to persons of ordinary skill in the art. The technique. A compound of the formula V can be converted to an acetamide of the formula IV by reaction with acetyl chloride or acetic anhydride, in the presence of a base, in a reaction-inert solvent. Suitable solvents include methylene chloride, dichloroethane, tetrahydrofuran and dioxane, preferably methylene chloride. Suitable bases include trialkylamines such as triethylamine and tributylamine, dimethylaminopyridine and potassium carbonate, preferably triethylamine. The temperature of the aforesaid reaction is in the range of about 0 ° C to about 35 ° C, for about 1 hour to about 10 hours, preferably at about 25 ° C for about 3 hours. The acetamide of formula IV is cyclized to obtain a compound of formula III, by reaction with a dehydrating agent, in the presence of a catalyst, in a dry solvent inert to the reaction. Suitable dehydrating agents include acetic anhydride, phosphorus pentoxide, dicyclohexylcarbodiimide and acetyl chloride, preferably acetic anhydride. Suitable catalysts include sodium or potassium acetate, acetic acid, p-toluene sulphonic acid or boron trifluoride etherate, preferably sodium acetate, suitable solvents include dioxane, toluene, diglyme or dichloroethane, preferably dioxane. The temperature of the aforesaid reaction is in the range of about 80 ° C to about 110 ° C, for about 1 hour to about 24 hours, preferably a temperature of about 100 ° C is used for about 3 to 10 hours. Alternatively, the compound of formula V can be converted directly to a compound of formula III by reaction with acetic anhydride in the presence of an acid catalyst in a solvent. Suitable acidic catalysts include acetic acid, sulfuric acid or p-toluene sulfonic acid, preferably acetic acid. Suitable solvents include acetic acid, toluene or xylene, preferably acetic acid. The temperature of the above reaction is from about 20 ° C to about 150 ° C, for about 10 minutes to about 10 hours, preferably a temperature of about 120 ° C is used for about 2 to 5 hours. The compound of formula III, formed by any of the above processes, is reacted with an amine of the formula VIII in a polar protic solvent, in the presence of an acid catalyst, to form a compound of formula II. Suitable acidic catalysts include acetic acid, p-toluene sulfonic acid or sulfuric acid, preferably acetic acid. Suitable polar protic solvents include acetic acid, methane, ethanol or isopropanol, preferably acetic acid. The temperature of the reaction mentioned above is from about 20 ° C to about 117 ° C, for about 1 hour to about 24 hours, preferably a temperature of about 117 ° C is used for about 6 hours. Alternatively, a compound of formula IV can be converted directly to a compound of formula II by reaction with a dehydrating agent, an amine of formula VIII and a base, in a reaction-inert solvent. Suitable dehydrating agents include phosphorus trichloride, phosphorus oxychloride, phosphorus pentachloride, or thionon chloride, preferably phosphorus trichloride. Suitable bases include pyridine, lutidine, dimethylaminopyridine, triethylamine or N-methyl morpholine, preferably priridine. Suitable solvents include toluene, cyclohexane, benzene or xylene, preferably toluene. Under some circumstances, when the mixture of reagents is a liquid, the reaction can be carried out in the pure state. The reaction temperature, above is from about 50 ° C to about 150 ° C, for from about 1 hour to about 24 hours, preferably a temperature of about 110 ° C is used for about 4 hours. The compound of formula II is reacted with an aldehyde of the formula R 2 CHO in the presence of a catalyst and a dehydrating agent, in a suitable solvent, to form a compound of the formula I, wherein the broken line is a double bond. Suitable catalysts include zinc chloride, sodium acetate, aluminum chloride, tin chloride or boron trifluoride etherate, preferably zinc chloride or sodium acetate. Suitable dehydrating agents include acetic anhydride, methanesulfonic anhydride, trifluoroacetic anhydride or propionic anhydride, preferably acetic anhydride. Suitable polar solvents include acetic acid, dioxane, dimethoxyethane or propionic acid. The temperature of the aforesaid reaction is from about 60 ° C to about 100 ° C, for from about 30 minutes to about 24 hours, preferably a temperature of about 100 ° C is used for about 3 hours. Compounds of formula I in which the dashed line represents a single carbon-carbon bond, can be prepared by hydrogenation of the corresponding compounds in which the dashed line represents a carbon-carbon double bond, using conventional techniques that are well known for those skilled in the art. For example, the reduction of the double bond can be done with hydrogen gas (H2), using catalysts such as palladium on carbon (Pd / C), palladium on barium sulfate (Pd / BaS04), platinum on carbon (Pt / C) or tris (triphenylphosphine) rhodium chloride (Wilkinson's catalyst), in an appropriate solvent such as methanol, ethanol, THF, dioxane or ethyl acetate, at a pressure of about 1 to about 5 atmospheres and at a temperature of about 10 ° C to about 60 ° C, as described in Catalvtic Hydroqenation in Orqanic Synthesis, Paul Rylander, Academic Press Inc., San Diego, 1979, p. 31-63. The following conditions are preferred: Pd on carbon, ethyl acetate at 25 ° C and a hydrogen gas pressure of 15-60 psi (103,421-413,685 kPa). This procedure also provides for the introduction of hydrogen isotopes (deicr, deuterium, tritium) by replacing 1H2 with 2H2 or 3H2 in the above procedure. The compounds of the formula I can be separated into compounds of the formula la and Ib by High Pressure Liquid Chromatography (HPLC) using a chiral HPLC column and eluting with an appropriate solvent. A person of ordinary skill in the art will understand that many types of instruments can be used, columns and eluents, to separate the individual atropisomers. Suitable HPLC instruments include LC SpiderLing®, Waters 4000®, Hewlett Packard 1050® and Analytical Grade Thermo Separation Products HPLC. Suitable HPLCs are configured according to procedures well known to persons of ordinary skill in the art. Such a configuration invariably includes a pump, an injection hole and a detector. Suitable chiral columns can be purchased pre-filled or filled by a person of ordinary skill in the art. Suitable chiral columns include chiral columns OA, OD, OG, AD and AS, which can be purchased from Chiral Technologies Inc., 730 Springdale Drive, PO Box 564, Exton, PA 19341. A person of ordinary skill in the art will appreciate that for To separate the isomers of the invention, many other chiral communes purchased from other vendors may be suitable. The filling material can also be purchased with different sizes of the beads. The beads suitable for the preparative separations have a size of 20 micrometers in diameter. Perias suitable for analytical separation have a size of approximately 10 micrometers in diameter. The compounds of formula I, in which a basic group is present, can also be resolved by treatment with an enantiomerically pure acid in a suitable solvent to form separable diastereomeric salts. Suitable enantiomerically pure acids include camphorsulfonic acid, tartaric acid (and derivatives thereof), mandelic acid and lactic acid. Suitable solvents include alcohols, such as ethanol, methanol and butanol, toluene, cyclohexane, ether and acetone. Alternatively, a compound of formula V can be converted to a compound of formula II according to the procedures described in scheme 2. The compound of formula II thus formed can be converted to a compound of formula I according to the procedures of the scheme 1. Referring to scheme 2, a compound of formula V is reacted with a coupling reagent, an amine of formula VIII, described above, and a base, in a reaction-inert solvent, to form a compound of the formula VI. Examples of suitable coupling reagents that activate the carboxylic functionality are dicyclohexylcarbodiimide, N-3-dimethylaminopropyl-N-ethylcarbodiimide, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), carbonyl diimidazole (CDI) and diethylphosphoryl . Suitable bases include dimethylaminopyridine (DMAP), hydroxybenzotriazole (HBT) or triethylamine, preferably dimethylaminopyridine. The coupling is carried out in an inert solvent, preferably in an aprotic solvent. Suitable solvents include acetonitrile, dichloromethane, dichloroethane and dimethylformamide. The preferred solvent is dichloromethane. The temperature of the above reaction is generally from about -30 to about 80 ° C, preferably from about 0 to about 25 ° C. The compound of the formula VI is converted into a compound of the formula VII by reaction with acetyl chloride or acetic anhydride, in the presence of a base, in a reaction-inert solvent. Suitable solvents include methylene chloride, tetrahydrofuran and chloroform, preferably methylene chloride. Suitable bases include trialkylamines such as triethylamine and tributylamine, dimethylaminopyridine and potassium carbonate, preferably triethylamine. The temperature of the above reaction is in the range of about 0 ° C to about 35 ° C, for about 1 hour to about 10 hours, preferably a temperature of about 30 ° C is used for about 3 hours. The compound of formula VII is cyclized to obtain a compound of formula II, by reaction with triphenylphosphine, a base, and a dialkyl azodicarboxyiate, in a solvent inert to the reaction. Suitable bases include pyridine, triethylamine and 4-dimethylaminopyridine, preferably 4-dimethylaminopyridine. Suitable solvents include dimethylformamide, tetrahydrofumane and dioxane, preferably dioxane. The temperature of the above reaction is in the range of about 25 ° C to about 125 ° C, for about 1 hour to about 24 hours, preferably a temperature of about 100 ° C is used for about 8 to 15 hours. The compound of the formula II can be converted into a compound of the formula I according to the procedure described in scheme 1. The compounds of formula II can also be obtained according to the procedures described in Miyashita, and others, Heterocycles, 42, 2, 691-699 (1996). In scheme 3, the compound of formula II is converted into the corresponding compound of formula VIII by reaction with a base, such as lithium diisopropylamide, in a polar aprotic solvent such as tetrahydrofuran. The solution is stirred at room temperature between about -100 ° C and about 0 ° C, preferably at -78 ° C for a period of time between about 15 minutes and about 1 hour, preferably about 30 minutes. The anionic product thus formed is reacted with a tetrahydrofuran solution of an aldehyde of the formula R 2 CHO. The aldehyde solution can be added to the anion solution (normal addition) or the anion solution can be added to the aldehyde solution (reverse addition). Although the two methods can be used to produce compounds of formula VIII, reverse addition is preferred. The resulting reaction mixture is stirred for a period of time between about 15 minutes and about 1 hour, preferably about 30 minutes, at a temperature between about -100 ° C, preferably -78 ° C, and then it is allowed to warm to the room temperature. In reaction 2 of scheme 3, the compound of formula VIII is converted to the corresponding compound of formula I by reaction of VIII with a dehydrating agent, such as trifluoroacetic anhydride, in a dry, reaction-inert solvent, such as dioxane, toluene, diglyme or dichloroethane, preferably dioxane. The reaction mixture is stirred at a temperature between about 0 ° C and about 50 ° C, preferably at room temperature, for a period of time between about 1 hour and about 14 hours, preferably about 12 hours.

The compounds of formula I, in which the dashed line represents a single carbon-carbon bond, can be prepared by hydrogenation of the corresponding compounds in which the dotted line represents a carbon-carbon double bond, using conventional techniques that are well known to those skilled in the art. For example, the reduction of the double bond can be carried out with hydrogen gas (H2), using catalysts such as palladium on carbon (Pd / C), paiate on barium sulfate (Pd / BaSO4), platinum on carbon (Pt / C) or tris (triphenylphosphine) rhodium chloride (Wilkinson's catalyst), in an appropriate solvent such as methanol, ethanol, THF, dioxane or ethyl acetate, at a pressure of about 1 to about 5 atmospheres and at a temperature of about 10 ° C to about 60 ° C, as described in Catalytic Hvdrogenation in Organic Svnthesis, Paul Rylander, Academic Press Inc., San Diego, 1979, p. 31-36. The following conditions are preferred: Pd on carbon, ethyl acetate at 25 ° C and hydrogen gas pressure of 15-20 psi (103.421-137.895 kPa). This method also provides for the introduction of hydrogen isotopes (ie, deuterium, tritium) by replacing 1H2 with H2 3H2 in the above procedure. Unless otherwise indicated, the pressure of each of the above reactions is not critical. Generally, the reactions will be carried out at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).

When R2 is heteroaryl, a person of ordinary skill in the art will understand that the heteroaryl is selected from the group consisting of pyridin-2-yl, 1,3-pyrazin-4-yl, 1,4-pyrazin-3-yl, 1,3-pyrazin-2-yl, pyrrolo-2-yl, 1,3-imidazol-4-yl, 1,3-imidazol-2-yl, 1,4-triazol-2-yl, 1 3-oxazol-4-yl, 1,3-oxazol-2-yl, 1,3-thiazol-4-yl, 1,3-thiazol-2-yl, 1,4-oxadiazol-3-yl, 1, 2,4-oxadiazol-5-yl, fur-2-yl, 1,3-oxazol-5-yl and 1,4-oxadiazol-2-yl, wherein said heteroaryl may be optionally substituted in any of the atoms capable of forming an additional bond, with a maximum of up to three substituents. The compounds of the formula which are basic in nature can form a wide variety of different salts with various inorganic and organic acids. Although such salts have to be pharmaceutically acceptable to be administered to animals, it is often desirable in practice to initially isolate a compound of the formula la from a reaction sample as a pharmaceutically unacceptable salt, then simply convert the latter into the compound of free base by treatment with an alkaline reagent and subsequently converting the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the basic compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the organic acid or mineral chosen, in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol . After careful evaporation of the solvent, the desired solid salt is obtained. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the basic compounds of this invention, are those which form non-toxic addition salts, ie salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide salts , acid, acetate, lactate, citrate or citrate acid, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1, 1 ' -methylene-bis- (2-hydroxy-3-naphthoate)]. The compounds of formula which are acidic in nature, are capable of forming base salts with various cations, pharmacologically acceptable. Examples of such salts include the alkali metal or alkaline earth metal salts and, in particular, the sodium and potassium salts. All these salts are prepared by conventional techniques. The chemical bases that are used as reagents for preparing the pharmaceutically acceptable base salts of this invention, are those that form non-toxic base salts with the acidic compounds of formula I described herein. These non-toxic base salts include those derived from pharmacologically acceptable cations such as sodium, potassium, calcium, magnesium, etc. These salts can be easily prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations and, subsequently, evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they can also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide and then evaporating the resulting solution until the dryness, in the same manner as indicated above. In any case, stoichiometric amounts of reagents are preferably employed to ensure that the reaction is completed and that maximum yields of the desired final product are obtained. The compounds of formula la and pharmaceutically acceptable salts thereof (hereinafter also referred to as active compounds of the invention) are useful for the treatment of neurodegenerative and CNS trauma related conditions and are potent antagonists of the AMPA receptor. Therefore, the active compounds of the invention can be used in the treatment or prevention of cerebral deficits subsequent to or resulting from cardiac bypass surgery and grafts, stroke, cerebral ischemia, spinal cord trauma, head trauma, Alzheimer's disease , Huntington's disease, amyotrophic lateral sclerosis, epilepsy, AIDS-induced dementia, perinatal hypoxia, hypoxia (such as conditions caused by strangulation, surgery, smoke inhalation, asphyxia, drowning, airway obstruction, electrocution or overdose of drug or alcohol), cardiac arrest, hypoglycemic neuronal injury, opioid tolerance, withdrawal syndrome (such as that produced by alcoholism and drug addiction, including opiate addiction, cocaine and nicotine), idiopathic and induced Parkinson's disease by drugs or cerebral edema; muscle spasms, migraines, urinary incontinence, psychosis, seizures, chronic or acute pain, eye injuries, retinopathy, retinal neuropathy, tinnitus, anxiety, emesis and tardive dyskinesia. The in vitro and in vivo activity of the compounds of the invention with respect to the antagonism of the AMPA receptor can be determined by methods available to a person of ordinary skill in the art. A method for determining the activity of the compounds of the invention is by the inhibition of pentylenetetrazole (PTZ) -induced attacks. Another method for determining the activity of the compounds of the invention is by blocking the uptake of 45Ca2 + induced by the activation of AMPA receptor. A specific method for determining the activity of the compounds of the invention in the inhibition of pentylenetetrazole (PTZ) -induced attacks in mice can be determined according to the following procedure. This essay examines the ability of compounds to block attacks and death produced by PTZ. The measures taken are latency for clonic and tonic attacks and death. The Dl50 values are determined based on percent protection. As subjects for these experiments, CD-1 male mice from Charles River, weighing 14-16 g after arrival and 25-35 g at the time of testing, serve. The mice are enclosed, 13 per cage, under conventional laboratory conditions, in a light cycle L: O / 7 a.m .: 7 p.m. for at least 7 days before the experimentation. Food and water are available ad libitum until the time of the trial. All compounds are administered in a volume of 10 ml / kg. The vehicles of the drug will depend on the solubility of the compound, but the selection will typically be made using saline, distilled water or E: D: S / 5: 5: 90 (5% emulfor, 5% DMSO and 90% solution salina) as an injection vehicle. The mice are administered the test compounds or the vehicle (i.p., s.c. or p.o.) and placed in plexiglass cages in groups of five. At a predetermined time after these injections, the mice receive an injection of PTZ (i.p., 120 mg / kg) and place them in individual plexiglass cages. The measures taken during this five-minute test period are: (1) latency for clone attacks, (2) latency for tonic attacks, and (3) latency for death. The treatment groups are compared to the vehicle-treated group by Kruskal-Wallis, Anova and Mann-Whítney U (Statview) trials. The protection percentage for each group is calculated (number of subjects that do not show attack or death as indicated by a score of 300 secs.) In each measurement. The values of DI50 are determined by prohibit analysis (Biostat). Another method for determining the activity of the compounds is to determine the effect of the compounds on motor coordination in mice. This activity can be determined according to the following procedure. As subjects for these experiments, CD-1 male mice from Charles River, weighing 14-16 g after arrival and 23-25 g at the time of testing, serve. The mice are enclosed, 13 per cage, under conventional laboratory conditions in a light cycle L: 0/7 a.m .: 7 p.m. for at least 7 days before the experimentation. Food and water are available ad libitum until the time of the trial. All compounds are administered in a volume of 10 ml / kg. The vehicles of the drug will depend on the solubility of the compound, but typically the selection will be made using saline, distilled water or E: D: S / 5: 5: 90 (5% emulfor, 5% DMSO and 90% solution salina) as an injection vehicle. The apparatus used in these studies consists of a group of five 13.34 x 13.34 cm wire mesh squares suspended on 11.43 cm steel rods connected to a 165.1 cm rod that is elevated 38. 1 cm above the laboratory table. These wire mesh boxes can be reversed. The mice are administered the test compounds or the vehicle (i.p., s.c. or p.o.) and placed in plexiglass cages in groups of five. At a predetermined time after these injections, the mice are placed on top of the wire mesh squares and they move abruptly so that the mice are suspended low. During the one minute test, the mice receive an evaluation of 0 if they fall from the screen, of 1 if they stay caught in the reverse position or of 2 if they climb to the top. The treatment groups are compared with the vehicle-treated groups with the Kruskal-Wallis and Mann-Whitney U (Statview) trials. Next, a specific procedure for determining the blocking of 45 Ca2 + uptake induced by the activation of the AMPA receptor is described.

Primary neuronal cultures Primary cultures of neurons from rat brain granules are prepared as described by Parks, TN, Artman, LD, Alasti, N., and Nemeth, EF, Modulation of N-Methyl-D-Aspartate Receptor-Mediated Increases In Cytosolic Calcium In Cultured Rat Cerebellar Granule Cells, Brain Res. 552, 13-22 (1992). According to this procedure, the cerebellums of 8-day-old CD rats are removed, cut into 1-mm pieces and incubated for 15 minutes at 37 ° C in Tyrode's solution without calcium or magnesium, containing 0.1 % of trypsin. The tissue is then ground using a fine-tipped Pasteur pipette. The cell suspension is introduced into 96-well tissue culture plates, coated with poly-D-lysine, at 10 5 cells per well. The medium consists of Minimum Essential Medium (MEM), with Earle salts, thermally inactivated 10% Fetal Bovine Serum, 2 mM L-glutamine, 21 mM glucose, Penicillin-Streptomycin (100 units per ml) and 25 mM KCl. After 24 hours, the medium is replaced with fresh medium containing 10 μM cytosine arabinoside to inhibit cell division. Crops should be used at 6-8 DIV.

Uptake of 45Ca2 + induced by activation of the AMPA receptor The effects of drugs on 45Ca2 + uptake induced by AMPA receptor activation can be examined in cultures of rat cerebellar granule cells. Cultures are preincubated in 96-well plates, for approximately 3 hours, in medium without serum, and then for 10 minutes in a balanced salt solution without Mg2 + (in mM: NaCl 120, KCl 5, NaH2P04 0.33 CaCl2 1.8, glucose 22.0 and HEPES 10.0 to pH 7.4) containing 0.5 mM DTT, 10 μM glycine and drugs at a final concentration 2X. The reaction is started by the rapid addition of an equal volume of the balanced salt solution containing 100 μM of the AMPA receptor agonist kainic acid and 45Ca2 + (final specific activity 250 Ci / mmol). After 10 minutes at 25 ° C, the reaction is stopped by aspirating the solution containing 45Ca2 + and washing the cells 5 times in an ice-cold balanced salt solution containing no added calcium and containing 0.5 mM EDTA. The cells are then lysed by overnight incubation in 0.1% triton-X100 and then the radioactivity in the lysate is determined. All the compounds of the invention that were tested had Cl50 values of less than 500 nM. The compositions of the present invention can be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention can be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration, or in a form suitable for administration by inhalation or insufflation. For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl hypromellose).; fillers (for example, lactose, microcrystalline cellulose or calcium phosphate); lubricants (for example, magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). The tablets can be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or may be presented as a dry product to be reconstituted with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives, such as suspending agents (for example, sorbitol syrup, hypromellose or hydrogenated edible fats); emulsifying agents (for example, lecithin or gum arabic); non-aqueous vehicles (e.g., almond oil, oil esters or ethyl alcohol) and preservatives (e.g., methyl or propyl p-hydroxybenzoate or sorbic acid). For buccal administration, the composition may take the form of tablets or dragees formulated in a conventional manner. The active compounds of the invention can be formulated for parenteral administration by injection, including conventional catheterization or infusion techniques. Formulations for injection may be presented in a unit dosage form, for example, in ampules or multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Alternatively, the active ingredient may be in powder form to be reconstituted with a suitable vehicle, eg, sterile, pyrogen-free water, before use. The active compounds of the invention can also be formulated in rectal compositions such as suppositories or retention enemas, which contain, for example, conventional suppository bases such as cocoa butter and other glycerides.

For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently supplied in the form of a solution or suspension from a container with a spray pump that is tightened or pumped by the patient, or in the form of a presentation of spraying aerosol from a pressurized container or a nebulizer, with the use of a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by arranging a valve to release a measured quantity. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, with gelatin) for use in an inhaler or insulator can be formulated so as to contain a powder mixture of a compound of the invention and a suitable powder base such as lactose or starch. A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to an average adult human, for the treatment of the aforementioned conditions (for example, apoplectic attack), is 0.01 to 20 mg / kg of the active ingredient per dosage unit, which could be administered, for example, from 1 to 4 times a day. Aerosol formulations for the treatment of the aforementioned conditions (e.g., apoplectic attack) in an average adult human being are preferably arranged so that each metered dose or "puff of aerosol" contains from 20 μg to 1000 μg of the compound of The invention The average daily dose with an aerosol will be within the range of 100 μg to 10 mg The administration can be carried out several times a day, for example 2, 3, 4 or 8 times, giving for example 1, 2 or 3 doses at a time The following examples illustrate the preparation of the compounds of the present invention Commercial reagents were used without further purification The melting points are uncorrected All NMR data were recorded at 250, 300 or 400 MHz in deuterium chloroform, unless otherwise specified, they are reported in parts per million (d) and refer to the deuterium stabilization signal of the solvent in the sample. Aqueous samples were made in dry glass containers, with dry solvents, under an inert atmosphere, for reasons of convenience and to maximize yields. Unless otherwise indicated, all reactions were shaken with a magnetic stir bar. Unless otherwise indicated, all mass spectra were performed using chemical impact conditions. The ambient temperature refers to a temperature of 20 to 25 ° C: EXAMPLE 1 (SH2-R3- (2-CHLOROFENLL) -6-FLUORO-4-OXO-3,4-DlHlDROQUINAZOLIN-2-IL1VINYLI-NICOTINONITRILE AND (R) -2- { 2- { 3- (2- CHLOROPHENlL) -6-FLURO-4- OXO-3,4-DIHYDRO-QUINAZOLIN-2-IL1-VINIL.} - NICOTINONITRILO The title compound of preparation 80 (1 mg) was dissolved in 1 ml of methanol and diluted 1:10 in 90/10 hexane / isopropanol with 0.1% diethylamine. An aliquot of 10 μl of this solution was injected into a ChiralPak AD High Pressure Liquid Chromatography column of 250 x 4.6 mm internal diameter (Chiral Technologies, Exton, PA, Part No. 19042). The detection was made with a Hewlett-Packard 1050 detector with a series of diodes at 2500 nanometers. For each peak of the chromatogram, all the scanning spectra were collected in a range of 190 to 600 nm. The resulting separation gave two peaks eluting 42,167 and 49,906 minutes, respectively. The spectra of all the components of the peak were identical to each other and identical to that of the racemate, confirming that the components are enantiomers.

EXAMPLE 2 IS) -3- (2-CHLOROPHENYL) -2-F2- (6-DIETHYLAMINOMETYLPYRIDIN-2-IL) VINYL-β-FLUORO-3H-QUINAZOLIN-4-ONA AND -3-F2-CHLOROPHENYL-2-r2-fß - DIETLLAMINOMETILPIRIDIN-2-IL) -VINIL-6-FLUORQ-3H-QUINAZOLIN-4-ONA The racemic product of Preparation 1 (120 mg) was dissolved in 12.4 ml of ethanol and injected with a syringe into a preparative HPLC column (Chiracel OD® 5 cm x 50 cm): The pure enantiomers were eluted using 10% ethanol. % in hexane at a flow rate of 100 ml per minute. The eluent was monitored with ultraviolet detection at 250 nm. Two fractions were collected, the first component centered around an elution time of 10.7 min and the second around an elution time of 15.0 minutes. The total time of the cycle for the test was 40 minutes. The spectra of each component of the peaks were identical to each other and identical to that of the racemate, which means that the components are enantiomers. ([a] D = 43.5 C = 1, CH3OH) EXAMPLE 3 (s) -3- (2-chlorophenin-2-r2- (6-ethylammonityl-pyridin-2-yl) -vinyl-6-fluoro-3h-quinazolin-4-one and (-) -3- (2-chlorophenyl) -2-r2- (6-ethylaminomethyl-pyridin-2-yl) -vinyl-6-fluoro-3h-quinazolin-4-one The racemic product of preparation 24 (150 mg) was dissolved in 5 ml of sodium propane with 0.1% diethylamine. The solution was then applied to an HPLC column (Chiracel OD® 5 X 50 cm) and eluted with a 30/70 mixture of isopropanol / hexane with 0.1% diethylamine at a flow rate of 100 ml per minute. The eluent was monitored with ultraviolet detection at 265 nm. Two fractions were collected, the first component centered around an elution time of 13.8 min and the second around an elution time of 13.8 min and the second around an elution time of 20.1 min. The spectra of each component of the peaks were identical to each other and identical to that of the racemate, confirming that the components are enantiomers. ([a] D = +47.2 C = 0.25, CH3OH) ([a] D = 47.6 C = 0.25, CH3OH) EXAMPLES 4-15 Examples 4-15 were prepared according to procedures analogous to those of Example 1.

Table 1 PREPARATION 1 3- 2-chlorophenyl) -2-r2- (6-diethylamnomethylpyridin-2-yl) -vinyl-6-fluoro-3h-quinazolin-4-one Procedure A 6-fluoro-2-methylquinoxalin-4-one A solution of 12.95 g (70.0 mmoles) of 2-nitro-5-fluorobenzoic acid in 200 ml of glacial acetic acid and 20 ml of acetic anhydride was treated with 0.625 g of 10% palladium on carbon and reduced to a pressure initial 54.5 psi (375.764 kPa). The hydrogen uptake was complete after two hours. The catalyst was removed by filtration and the filtrate was heated to reflux for two hours, after which TLC (1: 1 hexane / ethyl acetate) indicated that the reaction was complete. The reaction mixture was evaporated to a more semicrystalline which was dissolved in a minimum amount of 2-propanol and stirred in an ice bath for one hour. The crystalline solid was filtered off, washed with a minimum amount of cooled 2-propanol and dried in air to give 5.79 g (46% of the desired product as a brown solid, mp 127.5-128.5 ° C. Slothouwer, JH, Red., Trav. Chim. Pavs-Bas., 33, 336 (1914) describes a synthesis of 5-fluoro-2-nitrobenzoic acid.

Procedure B 3- (2-chlorophenyl) -6-fluoro-2-methyl-4- (3H) -quinazolinone A solution of 2.50 g (14.0 mmol) of 6-fluoro-2-methylquinoxalin-4-one and 1.96 g (15.4 mmol) of 2-chloroaniline in about 20 ml of glacial acetic acid was heated to reflux under a nitrogen atmosphere for 6 hours. The majority of the solvent was evaporated from the cooled reaction mixture and the residues were taken up in ethanol and cooled. After 6 days in the refrigerator, the crystals formed were separated by filtration, washed with a minimum amount of cooled ethanol and air dried to give 1.79 g (44%) of the product, m.p. 137-138 ° C.

Procedure C 6- (2-R3- (2-chlorophenyl) -6-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl-vinyl) -pyridine-2-carbaldehyde A catalytic amount (approximately 100 mg) of anhydrous zinc chloride was added to a solution of 576 mg (2.0 mmol) of 3- (2-chlorophenyl) -6-fluoro-2-methyl-4 (3H) -quinazolinone and 270 mg (2.0 mmoles) of 2,6-pyridinedicarboxaldehyde in 20-25 ml of dioxane and 1.0 ml of acetic anhydride.

The reaction mixture was heated to reflux under a nitrogen atmosphere for 3 hours, until TLC indicated that the starting materials had been consumed. The cooled reaction mixture was poured into water and the mixture was extracted with ethyl acetate. The combined extracts were dried with brine and magnesium sulfate, treated with decolorizing carbon, filtered and the solvent removed to give the desired product. This was taken up in 2: 1 ether / pentane and the crystals were filtered to give 266 mg of the product, 33%, m.p. 247-248 ° C. Papadopoulos, et al., J. Org. Chem. 31 615 (1966) describe a synthesis of pyridine-2,6-dicarboxaldehyde.

Procedure D 3- (2-chlorophenyl) -2-r2- (6-diethylaminomethylpyridin-2-yl) -vinyl-6-fluoro-3H -quinazolin-4-one A solution of 65 mg (0.16 mmol) of 6-. { 2- [3- (2-chlorophenyl) -6-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl) -vinyl) pyridine-2-carbaldehyde in 10 ml of methylene chloride, at room temperature environment, under a nitrogen atmosphere, was treated with 3 drops of diethylamine and 73 mg (0.34 mmoles) of sodium triacetoxyborohydride. After stirring for 2.5 hours at room temperature, the solvent was evaporated, the residues were partitioned between dilute hydrochloric acid and ether and stirred for 30 minutes. The ether layer was separated, the aqueous layer was extracted again with ether and the ether extracts were discarded. The aqueous acid solution was adjusted to a pH of about 14 with 10% sodium hydroxide (cooling with an ice bath) and then extracted twice with ether. The combined ether extracts were dried with brine and with magnesium sulfate and the solvent was evaporated. After an attempt to form the mesylate salt, the treated free base, in ethyl acetate, was treated with 7.5 mg (0.06 mmol) of maleic acid dissolved in a little ethyl acetate. In the resulting solutions, crystals were formed which were filtered and washed with ethyl acetate to give 22 mg of the monomaleate salt, (24%), m.p. 170.5-171.5 ° C.

Preparations 2-50 The preparations 2-50 were obtained according to procedures analogous to those of preparation 1.

Table 2 Preparation 46 NMR: (CDCb) (2.05 (3H, s), 4.95 (2H, s), 6.12 (1H, d, J = 15), 6.40 (1H, s), 6.50 (1H, s), 7.35-7.37 (1H , m), 7.47-7.55 (3H, m), 7.63-7.65 (1H, m), 7.72-7.75 (2H, m), 7.89-7.92 (1H, m).

Preparation 47 NMR: (CDCl 3) (7.10-7.12 (1H, m), 7.15 (1H, d, J = 15), 7.38-7.40 (1H, m), 7.48-7.55 (3H, m), 7.63-7.65 (1H , m), 7.81-7.84 (1 H, m), 7.92- ?? (2H, m), 8.64 (2H, s).

Preparation 48 NMR: (CDCl 3) (7.98 (dd, 1H), 7.85 (m, 1H), 7.50-7.70 (m, 6H), 7.12 (d, 1H), 7.05 (d, 1H), 6.00 (d, 1H), 5.15 (d, 1H), 2.46 (s, 3H).

Preparation 49 NMR: (CDCl 3) (7.90 (dd, 1H), 7.70 (dd, 1H), 7.60 (m, 1H), 7.40-7.55 (m, 4H), 7.20-7.35 (m, 2H), 7.00 (d, 1H ), 3.65 (s, 2H), 3.25 (m, 2H), 2.75 (m, 2H), 2. 55 (q, 4H), 1.00 (t, 6H).

Preparation 50 NMR: (CDCl 3) d 2.92 (1 H, m), 3.10 (2 H, m), 3.42 (1 H, m), 6.80-6.88 (1 H, m), 6.99-7.06 (1 H, m), 7.12- 7.20 (2H, m), 7.34-7.42 (1H, m), 7.56-7.72 (4H, m), 7.88-7.96 (1H, m), 8.56 (1H, m).

Preparation 51 6-FLUORO-2-r2- (2-METHYL-TIAZOL-4-IU-VINYL1-3- (2-METHYL-PHENHY-3H-QUINAZOLIN-4-ONA Anhydrous zinc chloride (0.136 g, 1.0 mmol) was fused with nitrogen purge in a round bottom flask with open flame. The reaction vessel was allowed to return to room temperature and then dioxane (10 ml) was added. To this mixture were added 6-fluoro-2-methyl-3- (2-methyl-phenyl) -3H-quinazolin-4-one (0.134 g, 0.5 mmol), acetic anhydride (0.141 ml, 1.5 mmol) and 2- methylthiazole-4-carboxaldehyde (0.191 g, 1.5 mmol). The reaction mixture was heated to reflux for 3.5 hours, after which the reaction was allowed to cool to room temperature.

When the reaction was cooled to room temperature, it was diluted with water. The resulting mixture was extracted repeatedly with chloroform. The chloroform extracts were combined and the resulting chloroform layer was washed with water and brine, dried over sodium sulfate and concentrated to leave a dark residue. This residue was triturated with ether, filtered and dried to yield 0.04 g (21%) of 6-fluoro-2- [2- (2-methyl-thiazol-4-yl) -vinyl] -3- (2- methyl-phenyl) -3H-quinazolin-4-one in the form of a tan solid. Melting point: 211-212 ° C; NMR: (CDCl 3) d 7.91 (dd, J = 3, 8, 3 Hz, 1 H), 7.87 (d, J = 15 Hz, 1 H), 7.75 (dd, J = 5, 9 Hz, 1 H) , 7.49 (dt, J = 3, 9 Hz, 1H), 7.42 (m sim., 3H), 6.61 (d, J = 15 Hz, 1H), 2.60 (s, 3H), 2.09 (s, 3H).

Preparation 52 3- (2-CHLORO-PHENYL) -6-FLUORO-2-r2- (2-METHYL-TIAZOL-4-IL) -VINIL1-3H-QUINAZOLIN-4-ONA Anhydrous zinc chloride (0.133 g, 0.98 mmol) was fused with nitrogen purge in a round bottom flask with open flame. The reaction vessel was allowed to return to room temperature, after which dioxane (7 ml) was added. To this mixture were added 3- (2-chloro-phenyl) -6-fluoro-2-methyl-3H-quinazolin-4-one (0.14 g, 0.49 mmol), acetic anhydride (0.138 mL, 1.46 mmol) and 2-methylthiazole-4-carboxaldehyde (0.185 g, 1.46 mmol in 4 ml of dioxane). The reaction was heated to reflux for 4 hours, after which the reaction was allowed to cool to room temperature.

When the reaction had cooled to room temperature, it was diluted with water. The mixture was extracted repeatedly with chloroform. The chloroform extracts were combined to a chloroform layer which was washed with water and brine, dried over sodium sulfate and concentrated to give a dark residue. This residue was triturated with ether, filtered and dried to yield 0.16 g (57%) of 3- (2-chloro-phenyl) -6-fluoro-2- [2- (2-methyl-thiazol-4-yl. ) -vinyl] -3H-quinazolin-4-one in the form of a chestnut solid. Melting point: 231-232 ° C. NMR d 7.87-7.84 (m, 2H), 7.80 (dd, J = 4.8 9 Hz, 1 H), 7.63-7.61 (m, 1 H), 7.52-7.47 (m, 3H), 7.38-7.35 (m, 1 H), 7.20 (s, 1H), 6.60 ( d, J = 15 Hz, 1H), 2.60 (s, 3H). Analysis calculated for C20H? 3CIFN3OS: C, 60.45; H, 3.27; N, 10.58. Found: C, 59.68; H, 3.17; N, . 44 PREPARATION 53 2-r2- (2-Dimethylaminomethyl-thiazol-4-yl) -vinin-6-fluoro-3- (2-fluoro-phenyl) -3h-quinazolin-4-one Anhydrous zinc chloride (0.106 g, 0.78 mmol) was fused with nitrogen purge in a round-bottom flask with open flame. The reaction vessel was allowed to return to room temperature, after which dioxane (6 ml) was added. To this mixture, 6-fluoro-3- (2-fluoro-phenyl) -2-methyl-3H-quinazolin-4-one (0.108 g, 0.39 mmol), acetic anhydride (0.111 mL, 1.18 mmol) were added. and 2-dimethylaminomethylthiazole-4-carboxaldehyde (0.280 g, 1.18 mmol in 4 ml of dioxane). The reaction was refluxed for four days, after which it was allowed to cool to room temperature and diluted with water. Sodium carbonate was added until the mixture became basic. The mixture was extracted repeatedly with chloroform. The chloroform extracts were combined to a chloroform layer which was washed with aqueous bisulfite, water and brine and finally dried over sodium sulfate and concentrated to give a dark residue. This residue was triturated with ether, filtered and dried to yield 0.051 g (31%) of 2- [2- (2-dimethylaminomethyl-thiazol-4-yl) -vinyl] -6-fluoro-3- (2- fluoro-phenyl) -3H-quinazolin-4-one in the form of a chestnut solid. Melting point: 163-165 ° C; NMR d 7.90 (dd, J = 3, 8.5 Hz, 1 H), 7.88 (d, J = 15 Hz, 1H), 7.76 (dd, J = 5.9 Hz, 1H), 7.53 (m, 2H ), 7.33 (m, 4H), 6.74 (d, J = 15 Hz, 1 H), 2.48 (sa, 5H), 1.58 (s at 3H). Analysis calculated for C22H18F2N4? S 0.75 H20: C, 60.34; H 4.46; N, 12.80. Found: C, 60.37; H, 4.38; N, 12.39.

PREPARATION 54 3- (2-Bromo-phenyl) -6-fluoro-2-r2- (2-methy1-thiazol-4-yl) -vinn-3h-quinazolin-4-one Anhydrous zinc chloride (0.150 g, 1.1 mmol) was fused with nitrogen purge in a round bottom flask with open flame. The reaction vessel was allowed to return to room temperature, after which dioxane (5 ml) was added. To this mixture, 3- (2-bromo-phenyl) -6-fluoro-2-methyl-3H-quinazolin-4-one (0.182 g, 0.55 mmol), acetic anhydride (0.156 mL, 1.65 mmol) and 2-Methylthiazole-4-carboxaldhyde (0.209 g, 1.65 mmol in 3 ml of dioxane) The reaction was heated to reflux for 3 hours and then cooled to room temperature.When the reaction had cooled to room temperature, the reaction was cooled to room temperature. The resulting mixture was extracted repeatedly with chloroform.The combined chloroform layers were washed with water and brine, then dried over magnesium sulfate and then concentrated to give a dark residue.This residue was triturated with ether, filtered and dried to yield 0.116 g (52%) of 3- (2-bromo-phenyl) -6-fluoro-2- [2- (2-methyl-thiazole-4-ii) -vinyl] -3H -quinazolin-4-one in the form of a chestnut solid Melting point: 233-234 ° C; NMR d 7.96-7.90 (m, 1 H), 7.90 (d, J = 15 Hz, 1H), 7.77-7.75 (m, 2H), 7.55-7.53 (m, 2H), 7.46-7.38 (m, 2H) , 7.21 (s, 1 H), 6.60 (d, J = 15 Hz, 1 H), 2.61 (s, 3H). Analysis calculated for C2oH13BrFN3? S 0.5H2O: C, 53.22; H, 3.10; N, 9.31. Found: C, 53.07; H, 2.93; N, 9.25.

PREPARATION 55 3- (2-Chloro-phenin-2-f2- (2-methyl-thiazol-4-yl) -vinin-3h-auinazolin-4-one Anhydrous zinc chloride (0.136 g, 1.0 mmol) was fused with nitrogen purge in a round bottom flask with open flame. The reaction vessel was allowed to return to room temperature, after which dioxane (10 ml) was added. To this mixture, 3- (2-chloro-phenyl) -2-methyl-3H-quinazolin-4-one (0.135 g, 0.50 mmol), acetic anhydride (0.141 mL, 1.5 mmol) and 2-methylthiazole-4 were added. -carboxaldehyde (0.191 g, 1.5 mmol). The reaction was refluxed for 3 hours and then allowed to cool to room temperature. When the reaction had cooled to room temperature, it was diluted with water. The resulting mixture was extracted repeatedly with chloroform. The combined chloroform layers were washed with water and brine, dried over sodium sulfate and then concentrated to give a brown waxy solid. This residue was triturated with ether, filtered and dried to yield 0.139 g (73%) of 3- (2-chloro-phenyl) -2- [2- (2-methyl-thiazol-4-yl) -vinyl] -3H-quinazolin-4-one in the form of a tan solid. Melting point: 219-221 ° C; NMR d 8.30 (d, J = 7.8 Hz, 1 H), 7.91 (d, J = 15 Hz, 1 H), 7.78 (m, 2H), 7.63 (m, 1 H), 7.48 (m, 3H), 7.38 (m, 1H) (s, 1 H), 6.63 (d, J = 15 Hz, 1 H), 2.61 (s, 3H). Analysis calculated for C20H14CLN3OS.O.5 H20: C, 61.85; H, 3.87; N, 10.82. Found: C, 61.83; H, 3.75; N, 10.55.

PREPARATION 56-68 The compounds of Table 1 were obtained essentially by the same procedures as those exemplified for preparations 51-55.

Preparation 69 2-DIMETHYLAMINE-METHYL-1-AZOL-4-CARBOXALDEHYDE To a suspension of 2-dimethylaminothioacetamide hydrochloride (7.7 g, 50 mmol) ethanol (100 ml), ethyl bromopyruvate (6.3 ml) was added. The mixture was refluxed for 6 hours and then cooled to room temperature. Additional ethyl bromopyruvate (3.2 ml for a total of 75 mmol) was added and the reaction was heated at reflux for a further 2.5 hours. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between water and ethyl acetate and brought to a pH of 10 with the addition of solid potassium carbonate. The phases were separated and the aqueous layer was extracted with ethyl acetate. The combined organic phase was washed with water and brine, then dried over sodium sulfate and concentrated to yield an amber oil. This oil was purified by flash chromatography on silica gel (120 g). Elution was performed as shown below: 2% methanol / chloroform, 200 ml, fronts; 10% methanol / chloroform 75 ml, nothing; 750 ml, 10.7 g (100%) of ethyl 2-dimethylaminomethylthiazole-4-carboxylate in the form of a light yellow oil having: NMR d 8.07 (d, J = 1.4 Hz, 1H), 4.32 (q, J = 7 Hz, 2H), 3.73 (s, 2H), 2.28 (s, 6H), 1.31 (t, J = 7 Hz, 3H). The material was suitable for use without further purification.

To a mixture of lithium aluminum hydride (4.5 g, 119 mmol) in ice-cold tetrahydrofuran (100 ml), ethyl 2-dimethylaminomethylthiazole-4-carboxylate (8.5 g, 39.7 g) was added dropwise over 40 minutes. mmoles in 40 ml of tetrahydrofuran), maintaining an internal temperature of 5-10 ° C. The mixture was stirred at this temperature range for 90 minutes. The reaction was carefully quenched with saturated ammonium chloride (30 ml). The resulting gray suspension was stirred for 15 minutes and filtered through celite. The layer was washed well with ethyl acetate. The filtrate was washed with brine and dried over sodium sulfate. The concentration of this organic solution gave 4.2 g (62%) of 2-dimethylaminomethyl-4-hydroxymethylthiazole in the form of an amber oil having: NMR d 7.12 (s, 1H), 4.71 (s, 2H), 3.73 ( s, 2H), 2.50 (s, 1H), 2.32 (s, 6H). The material was used without further purification. A solution of 2-dimethylaminomethyl-4-hydroxymethyl-azole (4.2 g, 27.3 mmol) in methylene chloride (200 ml) was treated with Dess-Martin reagent (14.5 g)., 34.1 mmoles). The mixture was stirred at room temperature for 24 hours. More Dess-Martin reagent (2.9 g) was added and the mixture was stirred for a further 4 hours. The reaction was quenched by the addition of saturated aqueous sodium thiosulfate (100 ml) and the pH of the resulting mixture adjusted to 10 by the addition of solid potassium carbonate. The mixture of the two phases was filtered. The phases were separated from the filtrate and the aqueous layer was extracted with methylene chloride. The combined organic layer was washed with brine, dried over sodium sulfate and concentrated to yield a yellow solid. This solid was purified by flash chromatography on silica gel (50 x 130 mm), eluting first with chloroform (200 ml) and then with 2% methanol / chloroform, and collecting 25 ml fractions. Fractions 51-80 were combined and concentrated to leave 2.9 g of a milky yellow oil. This oil was triturated with 50% ethereal chloroform and a solid was removed by filtration with 50% ethereal chloroform and a solid was removed by filtration. The filtrate was concentrated to give 2.6 g (62%) of 2-dimethylaminomethyl-thiazole-4-carboxaldehyde as a yellow oil. NMR d 9.95 (s, 1 H), 8.14 (s, 1 H), 3.81 (s, 2H), 2.36 (s, 6H). This product was used without further purification.

PREPARATION 70 2-METHYLOXAZOL-4-CARBOXALDEHIPO Ethyl 2-methyloxaxoline-4-carboxylate was prepared according to the published procedure (Heterocicles, 1976, 4, 1688). To a room temperature solution of ethyl 2-methyloxaxoxy-4-carboxylate (6.28 g, 40 moles) in benzene (300 ml), copper (I) bromide (6.31 g, 44 mmol) was added and then ethyl acetate. copper (II) (7.99 g, 44 mmol). To this mixture was added dropwise, for 15 minutes, tertiary butyl perbenzoate (11.4 ml, 60 mmol) and the reaction warmed slightly to the touch. The black mixture was refluxed for 24 hours, cooled to room temperature and filtered through a pad of celite (rinsed with ether). The filtrate was washed with aqueous ammonium chloride, water and brine, then dried over sodium sulfate and concentrated. The chestnut residue was purified by flash chromatography on silica gel (80 g) eluting with 40% ethyl acetate / hexane. After 100 ml of fronts, 20 ml fractions were collected. Fractions 11-22 were collected and concentrated to yield 4.27 g (69%) of ethyl 2-methyloxazole-4-carboxylate in the form of a yellow oil having: NMR d 8.04 (s, 1 H), 4.32 (q , J = 7 Hz, 2H), 2.46 (s, 3H), 1.33 (t, J = 7 Hz, 3H). This material was used without further purification. A solution of ethyl 2-methyloxazole-4-carboxylate (0.31 g, 2.0 mmol) in tetrahydrofuran (5 ml) was cooled to -65 ° C, and diisobutylaluminium hydride (4.1 ml) was added dropwise over 15 minutes. a 1N solution in toluene, 4.1 mmol). The solution was allowed to warm to room temperature and was stirred for 15 minutes. The reaction was cooled to 5 ° C and carefully quenched by the addition of methanol (2 mL). The reaction mixture was returned to room temperature and water (0.18 ml) was added followed by sodium fluoride (1.68 g). This mixture was stirred for 30 minutes, then dried with magnesium sulfate and filtered. The filtrate was concentrated and azeotropically distilled with chloroform to yield 0.215 g (96%) of 4-hydroxymethyl-2-methyloxazole in the form of a clear oil it had. NMR d 7.45 (s, 1H), 4.52 (d, J = 6 Hz, 2H), 3.41 (s a, 1 H), 2.42 (s, 3H). A solution of 4-hydroxymethyl-2-methyloxazole (0.79 g, 6.99 mmol) in methylene chloride (25 ml) was treated with Dess-Martin reagent (8.9 g, 20.97 mmol) and stirred for 24 hours. The reaction was stopped by the addition of saturated aqueous sodium thiosulfate and stirred for 30 minutes. The mixture was filtered. The filtrate was extracted repeatedly with methylene chloride. The combined organic layers were washed with saturated aqueous bicarbonate (twice), water and brine. The organic phase was dried over sodium sulfate and concentrated to an oily white solid. This residue was triturated with ether and filtered. The filtrate was concentrated to yield 0.541 g (69%) of 2-methyloxazoi-4-carboxaldehyde as a light yellow solid having: NMR d 9.88 (s, 1 H), 8.15 (s, 1 H), 2.52 ( s, 3H).

PREPARATIONS 71-87 The compounds of preparations 71-87 were prepared by procedures analogous to those of preparation 1.

TABLE 3 PREPARATION 88 3- (2-Chloro-phenyl) -6-fluoro-2- (2-pyridin-2-yl-ethyl) -3H-quinazolin-4-one hydrochloride A solution of 1.00 grams (2.65 mmoles) of 3- (2-chloro-phenyl) -6-fluoro-2- (2-pyridin-2-yl-vinyl) -3H-quinazolin-4-one was treated in about 100 ml of ethyl acetate, with 0.5 grams of 10% Pd on C and the resulting mixture was hydrogenated at about 2 cm of Hg for two hours, after which the uptake of hydrogen had ceased. The catalyst was removed by filtration with the aid of supercel (filter aid) and the ethyl acetate was removed by evaporation. The residues were dissolved in diethyl ether and treated with excess of a solution of HCl gas in diethyl ether. The product precipitated immediately and was allowed to stir for 3 hours, after which it was filtered off and dried in a stream of dry nitrogen. The product was 1.15 g (100%) of 3- (2-chloro-phenyl) -6-fluoro-2- (2-pyridin-2-yl-ethyl) -3H-quinazolin-4-one hydrochloride, a solid amorphous white PREPARATION 89 ß-Diethylaminomethyl-pyridine-2-carbaldehyde A suspension of 1500 g of 2,6-dibromopyridine (6.33 moles, 1. 0 equiv. MW 236.9) in 12 I (8 vi) of dry IPE, was kept under a nitrogen atmosphere overnight in a 22-l round bottom flask. The suspension was then cooled to -60 ° C and added dropwise 2532 ml of n-Buli (6.33 mmoles, 2.5 M in haxanes, 1.0 eq.) By means of an addition funnel, to maintain the temperature at 60 ° C. The reaction suspension was then stirred for 30 minutes. (The suspension is gradually cleared) TLC (50:50 hexane / methylene chloride) of an aliquot inactivated in methanol showed only traces of the starting material. Then dimethylformamide (775 ml, 6.96 mmol, 11 equiv., Pm 101, 15, d = 0.908) was added dropwise via the addition funnel, at a rate suitable to maintain the temperature at about -60 ° C. After stirring for 30 minutes, the suspension was heated to -10 ° C. In a 50 I vessel, 3 I of dry THF (2 vol) and 1313 ml of diethylamine (12.7 moles, 2.0 eq. MW 73.14, d = 0.707) were added. The reaction 22 I was transferred to cuvettes and then to the 50 1 vessel. At this time, 1475 g of sodium triacetoxyborohydride (6.96 moles, 1. 1 eq., PM 211.94). After warming to room temperature, 725 ml of glacial acetic acid (12.7 moles, 2.0 eq., MW 60, d = 1.05) were added dropwise. Then, the reaction was monitored by TLC (95: 5 methylene chloride / methanol) until the starting material disappeared. The reaction suspension is quenched by the addition of 15 I. Care should be taken with gas evolution. The final pH was about 10.5. The two phases were stirred for 60 minutes and then allowed to separate. The organic layer was washed with 3 x 1.5 i of water. The volatiles were removed in vacuo to provide the product as an oil which was kept under vacuum overnight to provide 1430 g of the title compound (93% of theory, crude). This material had sufficient purity to be used in the next stage as is. 1 H NMR (250 MHz, CDC b) d 7.46-7.48 (m, 2 H), 7.26-7.32 (m, 1 H), 3.67 (s, 2 H), 2.53 (q, J = 7.2 Hz, 4 H), 1.00 (t, J = 7.2 Hz, 6H), MS (M + 1) + = 243. The product of the previous stage (1430 g, PM 243.15, 5.88 moles, 1. 0 equiv.) Was dissolved in 0.5 I dry IPE and then transferred to an addition funnel. In a 22 I flask, 22 I (8 vol) more of IPE were placed. The system was purged with a nitrogen purge overnight. The 22 I flask was cooled to -78 ° C and 2470 ml of n-BuLi (2.5M, 6.17 mmol, 1.05 equiv.) Was added via a cannula to the 22 I flask, to < -60 ° C. The solution of CP-4574745 was added dropwise to keep the temperature below -60 ° C and stirred for a further 30 minutes. TLC analysis of an aliquot inactivated in methanol showed that the starting material had been consumed. 478 ml of anhydrous DMF (MW 73.14, d = 0.944, 6.17 moles, 1.05 equiv.) Was added at a suitable rate to maintain the temperature at about -60 ° C. The solution was allowed to warm to -20 ° C. At this time the reaction was stopped in a 50 I reactor in the following manner. The reaction solution was poured slowly into 980 ml (12N, 11.8 moles, 2.0 equiv.) Of concentrated HCl diluted to 7.5 I (5 vol). The layers were separated and the aqueous layer was extracted twice with 7.5 I of ethyl acetate (5 vol). The final pH is about 10.5. The combined organic layers were filtered to remove the particulates and the vacuum concentrated. The crude oil was treated with 917 g of sodium bisulfite (MW 104, 8.8 moles, 1.5 equiv.) In 15 I (10 vol.) Of water and 1.5 I (1 vol.) Of IPE. The biphasic mixture was stirred for one hour (with a pH of about 6.5). The mixture was treated with 985 g of sodium bicarbonate (MW 84, 11.8 moles, 2.0 equiv.) To give a pH of about 8.0. Caution must be exercised with the release of gas! The mixture was diluted with 7.5 I (5 vol.) Of ethyl acetate and the layers were separated. This was followed by two additional washes with 7.5 I of ethyl acetate. The aqueous layer containing the bisulfite adduct was tainted with 7. 5 I (5 vol.) Of ethyl acetate, followed by 412 g (MW 40, 10.3 moles, 1.75 equiv.) Of sodium hydroxide dissolved in 1.5 l of water. The pH was adjusted to 11 when necessary. The organic layer was separated and the aqueous layer was extracted twice more with 7.5 I (5 vol.) Of ethyl acetate. The volatiles were removed under vacuum to provide 904 g (80% of theory) of the title compound as an oil. This material had sufficient purity to be used directly in the next step. 1 H NMR (250 MHz, CDC b) d 10.2 (s, 1 H), 7.69-7.84 (n, 3 H), 3.78 (s, 2H), 2.58 (q, J = 7.2 Hz, 4H), 1.03 (t, J = 7.2 Hz, 6H). MS (M + 1) + = 193.

Claims

NOVELTY OF THE INVENTION CLAIMS

1. - An atropisomer of the formula wherein R2 is a phenyl group of the formula Ph2 or a five or six membered heterocycle; where said 6-membered heterocycle has the formula wherein "N" is nitrogen; wherein said positions of the ring "K", "L" and "M" can be independently selected from carbon and nitrogen, with the proviso that i) only one of "K", "L" and "M" can be nitrogen and ) when "K", "L" or "M" is nitrogen, then the respective R15, R16 or R17 is absent; where said five-membered heterocycle has the formula wherein said "T" is -CH-, N, NH, O or S; wherein said positions of the ring "P" and "Q" can be independently selected from carbon, nitrogen, oxygen and sulfur; with the proviso that (i) only one of "P", "Q" or "T" may be oxygen, NH or sulfur; (ii) at least one of "P", "Q" or "T" must be a heteroatom; and (iii) when "P" or "Q" is oxygen or sulfur, then the respective R15 or R16 is absent; where said Ph2 is a group of the formula

R3 is hydrogen, halo, -CN, -N02-, CF3, alkyl (C? -C6) or alkoxy (C6); R5 is hydrogen, C alquilo-alkyloid), halo, CF3lalkoxy (CrC6) or alkylthiol (CrC6); R6 is hydrogen, halo; R7 is hydrogen or halo; R8 is hydrogen or halo; R9 is hydrogen, halo, CF3, (C -? - C6) alkyl, optionally substituted with one to three halogen atoms, (C? -C?) Alkoxy optionally substituted with one to three halogen atoms, alkylthiol (C? -C6) ), amino- (CH2) s-, alkyl (C6C6) -NH- (CH2) S-, dialkyl (C6C6) -N- (CH2) s-, cycloalkyl (C3-C7) -NH- (CH2) s-, H2N- (C = 0) - (CH2) S-, alkyl (C? -C6), -NH- (C = 0) - (CH2) s-, dialkyl (C1-) C6) -N (C = OHCH2) s-, cycloalkyl (C3-C7) -NH- (C = O) - (CH2) s-, R130- (CH2) s-, R13O- (C = O) - ( CH2) s-, H (O = C) -NH- (CH2) s-, (C1-C6) alkyl- (O = C) -NH- (CH2) s-, (C1-C6) alkyl- (O = C) -N- (CH2) s-, H (O = C) -N- (CH2) s-, alkyl (C? -C6) alkyl (C? -C6) H- (C = 0) - (CH2) s-, (C1-C6) alkyl- (C = 0) -, hydroxy, hydroxy-alkyl-Ce) , Ci-CeJ-O-alkyloxy CrCe) or -CN; R10 is hydrogen or halo, R11 and R14 are independently selected from hydrogen, halo, CF3, (C? -C6) alkyl optionally substituted with one to three halogen atoms, (C-? - C6) alkoxy optionally substituted with one to three halogen atoms, alkylthio (C? -C6), amino- (CH2) p-alkyl (d-C6) -NH- (CH2) p-, dialkyl (d-C6) -N- (CH2) p- , (C3-C7) cycloalkyl-NH- (CH2) P-, amino- (C1-C6) alkyl -NH- (CH2) p-, alkyl (d-C6) -NH- (C1-C6) -NH alkyl - (CH2) p-, dialkyl (d-C6) -N-alkyl (d-C6) -NH- (CH2) P-, dialkyl (C? -C6) -N-alkyl (C? -C6) -N- (CH2) p-, N2H- (C = O) - I alkyl (d-C6) (CH2) P-, alkyl (CrCß) -HN- (C = OMCH2) p-, dialkyl (C? - C6) -N- (C = 0) - (CH2) p-, cycloalkyl (C3-C7) -NH- (C = 0) - (CH2) p-, R130- (CH2) p-, R130- (C = 0) - (CH2) p-, H (C = 0) -0-, H (C = 0) -0-alkyl (CrC6), H (0 = C) -NH- (CH2) p-, alkyl (D-C6) - (O = C) -NH- (CH2) p-, -CHO, H- (C = O) - (CH2) p-, alkyl (d-C6) - (C = O ) - (CH2) p-, alkyl (C? -C6) - (O = C) -N- (CH2) p-, H (C = O) -N- (CH2) p-, HO-alkyl (d) -C6) - II alkyl (C? -C6) alkyl (C? -C6) N- (CH2) P-, (C1-C6) alkyl- (C = O) -O- (CH2) p- , amino-alkyl (d-I) alkyl (d-C6) C6) - (C = 0) -0- (CH2) P-, (C1-C6) -NH-alkyl (C? -C6) - (C = 0) -0- (CH2) p-, dialkyl (d-C6) -N-alkyl (C? -C6) - (C = 0) -0- (CH2) P-, amino-alkyl (d) -C6) -0- (C = 0) - (CH2) P-, (C1-C6) alkyl -NH-alkyl (d-C6) -0- (C = 0) - (CH2) p-, dialkyl ( d-C6) -N- (C1-C6) alkyl -0- (C = 0) - (CH2) p-, hydroxy, hydroxy-alkyl (CrC6) -, hydroxy-alkyl (d-C6) -NH- (CH2) p-, alkyl (C? -C6) -O-alkyl (C? -C6), -CN, piperidine- (CH2) P-, pyrrolidine- (CH2) p-, and 3-pyrroline - (CH2) p-, wherein said piperidine, pyrrolidine and 3-pyrroline radicals of said piperidine- (CH2) p-, pyrrolidine- (CH2) p- and 3-pyrroline- (CH2) p- groups may be optionally substituted on any of the ring carbon atoms capable of supporting an additional bond, preferably with zero to two substituents, a substituent being independently selected from halo, CF3, optionally substituted (C? -C6) alkyl with one to three halogen atoms , (C? -C6) alkoxy optionally substituted with one to three atoms halogen, alkyltol (CrC6), amino- (CH2) p-, alkyl (d-C6) -NH- (CH2) P-, dialkyl (C? -C6) -N- (CH2) P-, cycloalkyl (C3) -C7) -NH- (CH2) p-, amino-alkyl (d-C6) -NH- (CH2) p-, (C1-C6) -NH-alkyl (C1-C6) -NH- ( CH2) p-, dialkyloid-CeJ-N-alkyloid-Ce) -NH- (CH2) P-, alkyloxyCi-CeI-O-alkyloCC), dialkyl (C6C6) -N-alkyl (C? -C.sub.be ) - 5 N- (CH2) P-, H2N- (C = 0) - (CH2) p-, alkyl- I alkyl (C? -C6) (C1-C6) -HN- (C = O) - (CH2) p-, dialkyl (C1-C6) -N- (C = 0) - (CH2) p-, cycloalkyl (C3-C7) -NH- (C = O) - (CH2) P- , R13O- (C = O) - (CH2) P-, H (O = C) -0-, H (0 = C) -0-alkyl (C10C6) -, H (O = C) -NH - (CH2) p-, alkyl (d-C6) - (O = C) -NH- (CH2) p-, -CHO, H- (C = O) - (CH2) P-, alkyl (d-C6) ) - (C = 0) -, aiquyl (C? -C6) - (C = 0) -N- (CH2) P-, H (O = C) -N- (CH2) p-, HO-alkyl ( C? -C6) - II «>; alkyl (C? -C6) alkyl (d-C6) N- (CH2) P-, alkyl (d-C6) - (C = 0) -O-NH- (CH2) p-, aminoalkyl (d-C6) ) - I aikyl (C? -C6) (d-C6) - (C = O) -O- (CH2) p-, (C1-C6) alkyl -NH- (C1-C6) alkyl- (C = O) -O- (CH2) p-, dialkyl (C1-C6) -N-alkyl (C? -C6) - (C = O) -O- (CH2) p-, hydroxy, hydroxy-aikyl (C ? -20 C6), hydroxy (C1-C6) alkyl -NH- (CH2) p- and -CN; R 12 is hydrogen, -CN or halo; R13 is hydrogen, alkyl (d-C6), alkyl (C? -C6) - (C = O) -, alkyl (d-C6) -O- (C = O) -, alkyl-CeJ-NH-alkyloid- Ce), dialkylCi CeJ-N-alkyloCi-Ce) -, alkyl (C? -C6) -NH- (C = O) - or dialkyl (d-C6) -N- (C = 0) -; R15 is hydrogen, -CN, alkyl (d-C6), halo, CF3, -CHO or alkoxy (d-Ce); R16 is hydrogen, -CN, (C6C6) alkyl, halo, CF3, -CHO or alkoxy (C6C6); R17 is hydrogen, -CN, alkyl (C6), amino-alkyl (C6-6), alkyloid-CeI-NH-alkyloid-Ce), dialkyl (C6-C6) -N-alkyl (C6-C6) ) -, halo, CF3, -CHO or alkoxy (C? -C6); n is an integer from zero to 3; each p is, independently, an integer from zero to 4; s is an integer from zero to 4; where the dashed link represents an optional double bond; and pharmaceutically acceptable salts of such compounds. 2. A compound according to claim 1, wherein R3 is hydrogen, halo or alkyl (C6C6).

3. A compound according to claim 1, wherein one of R5, R6, R7 or R8 is fluoro, bromo, chloro, methyl or trifluoromethyl.

4. A compound according to claim 1, wherein R5 is fluoro, bromo, chloro, methyl or trifluoromethyl.

5. A compound according to claim 2, wherein R5 is fluoro, bromo, chloro, methyl or trifluoromethyl.

6. A compound according to claim 1, wherein R2 is Ph2 and R9 is fluoro, chloro, -CN or hydroxy; or R11 is -CHO, chloro, fluoro, methyl, alkyl (C? -Ce) -NH- (CH2) p-, dialkyl (d-C6) -N- (CH2) p- or cyano.

7. A compound according to claim 2, wherein R2 is Ph2 and R9 is fluoro, chloro, -CN or hydroxy; or R11 is -CHO, chloro, fluoro, methyl, alkyl (C? -C6) -NH- (CH2) p-, dialkyl (C? -Ce) -N- (CH2) p- or cyano.

8. - A compound according to claim 1, wherein R2 is heteroaryl, wherein said heteroaryl is an optionally substituted six-membered heterocyclic compound, wherein "K", "L" and "M" are carbons or "K" and "L" are carbon and "M" is nitrogen (ie, pyrimidin-2-yl), or said heteroaryl is an optionally substituted five-membered heterocycle wherein "T" is nitrogen, "P" is sulfur and "Q" is "is carbon," T "is nitrogen or sulfur," Q "is nitrogen or sulfur and" P "is carbon or" T "is oxygen and" P "and" Q "are each a carbon.

9. A compound according to claim 1, wherein R2 is an optionally substituted six-membered heterocycle, wherein "K", "L" and "M" are carbons and wherein R14 is hydrogen, - CHO, chloro, fluoro, methyl, (C1-C6) alkyl -NH- (CH2) p-, dialkyl (d-C6) -N- (CH2) P- or cyano; R17 is hydrogen, -CHO, chloro, fluoro, methyl, alkyl (CrCe) -NH-alkylene d-Cß), dialkyl (d-C6) -N-alkyl (C? -C6) or cyano; or R15 or R16 are, independently, hydrogen, -CHO, chloro, fluoro, methyl or cyano.

10. A compound according to claim 1, wherein R2 is an optionally substituted six-membered heterocycle, wherein "K", "L" and "M" are carbons and R14 is hydrogen, -CHO, methyl , alkyl (d-C6) -NH- (CH2) P-, dialkyl (C? -C6) -N- (CH2) P- or cyano.

11. A compound according to claim 1, wherein R2 is an optionally substituted five-membered heterocycle, wherein "T" is nitrogen, "P" is sulfur and "Q" is carbon; and R14, R15 or R16 are each, independently, hydrogen, chloro, fluoro, methyl or cyano.

12. A compound according to claim 1, wherein R2 is an optionally substituted five-membered heterocycle wherein "T" is nitrogen or sulfur, "Q" is sulfur or nitrogen and "P" is carbon; and R14 or R15 are, independently, hydrogen, chloro, fluoro, methyl or cyano.

13. A compound according to claim 1, said compound being selected from the group consisting of: (S) -3- (2-chloro-phenyl) -2- [2- (5-diethylaminomethyl-2-fluoro- phenyl) -vinyl] -6-fluoro-3H-quinazolin-4-one; (S) -3- (2-chloro-phenyl-2- [2- (6-diethylamnomethyl-pyridin-2-yl) -vinyl] -6-fluoro-3H-quinazolin-4-one; ) -3- (2-chloro-phenyl) -2- [2- (4-diethylaminomethyl-pyridin-2-yl) -v] nyl] -6-fluoro-3H-quinazolin-4-one (S) - 3- (2-chloro-phenyl) -2- [2- (6-ethylaminomethyl-pyridin-2-yl) -v] nyl] -6-fluoro-3H-quinazolin-4-one; (S) - 3- (2-bromo-phenyl) -2- [2- (6-diethylaminomethyl-pyridin-2-yl) -vinyl] -6-fluoro-3H-quinazolin-pyridin-2-yl) -vinii ] -6-fluoro-3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -6-fluoro-2- [2- (6-methoxymethyl-pyridin-2-yl) -vinyl] -3H-quinazolin-4-one; (S) -3- (2-Chloro-phenyl) -6-fluoro-2- [2- (4-methyl-pyrimidin-2-yl) -vinyl] -3H-quinazolin-4-one; (S) -3- (2-chloro-phenyl) -6-fluoro-2-. { 2- [6- [isopropylamino-methyl] -pyridin-2-yl] ethyl} -3-H-quinazolin-4-one; and (S) -6-fluoro-2- [2- (2-methyl-thiazol-4-yl) -vinyl] -3- (2-methyl-phenyl) -3H-quinazolin-4-one. 14.- A pharmaceutical composition for treating or preventing a condition selected from cerebral deficits subsequent to or resulting from cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord trauma, head trauma, Alzheimer's disease, Huntington's Chorea , amyotrophic lateral sclerosis, epilepsy, AIDS dementia induced, perinatal hypoxia, hypoxia (such as conditions caused by strangulation, surgery, smoke inhalation, asphyxiation, drowning, choking airway, electrocution or drug overdose or alcohol ), cardiac arrest, hypoglycemic neuronal damage, opiate tolerance, addiction withdrawal (such as produced by alcoholism and drug addiction including opiate addiction, cocaine and nicotine), Parkinson's disease idiopathic and drug-induced or cerebral edema; spasms convulsions, chronic or acute pain, ocular lesions, retinopathy, retinal neuropathy, tinnitus, anxiety, emesis and tardive dyskinesia, in a mammal, comprising an amount of a compound according to claim 1 effective to treat or prevent such a condition, and a pharmaceutically acceptable vehicle. 15. The use of a compound according to claim 1 in the manufacture of a medicament for treating or preventing a condition selected between subsequent brain deficits or resulting from cardiac bypass surgery and grafts, stroke, cerebral ischemia, trauma of spinal cord, head trauma, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, AIDS-induced dementia, perinatal hypoxia, hypoxia (such as conditions caused by strangulation, surgery, smoke inhalation, asphyxia, drowning, obstruction of the respiratory tract, electrocution or overdose of drugs or alcohol), cardiac arrest, hypoglycaemic neuronal injury, opioid tolerance, withdrawal syndrome (such as that produced by alcoholism and drug addiction, including opiate addiction, cocaine and nicotine), idiopathic and drug-induced Parkinson's disease or cerebral edema; muscle spasms, migraines, urinary incontinence, psychosis, seizures, chronic or acute pain, ocular lesions, 5 retinopathy, retinal neuropathy, tinnitus, anxiety, emesis and tardive dyskinesia, in a mammal. 16. A pharmaceutical composition for treating or preventing a condition selected between subsequent brain deficits or resulting from cardiac bypass surgery and grafts, stroke, cerebral ischemia, spinal cord trauma, head trauma, Alzheimer's disease, Korea Huntington, amyotrophic lateral sclerosis, epilepsy, AIDS-induced dementia, perinatal hypoxia, hypoxia (such as ^ Conditions caused by strangulation, surgery, smoke inhalation, * Asphyxia, drowning, airway obstruction, electrocution or 15 drug or alcohol overdose), cardiac arrest, hypoglycaemic neuronal injury, opioid tolerance, withdrawal syndrome (such as that produced by alcoholism and drug addiction, including opiate addiction, cocaine and nicotine), Parkinson's disease idiopathic and induced by drugs or cerebral edema; muscle spasms, migraines, 20 urinary incontinence, psychosis, seizures, chronic or acute pain, eye lesions, retinopathy, retinal neuropathy, tinnitus, anxiety, emesis and tardive dyskinesia, in a mammal, comprising an effective amount to antagonize the AMPA receptor of a compound according to with claim 1, and a pharmaceutically acceptable carrier. 17. The use of an effective amount for antagonizing the AMPA receptor of a compound according to claim 1, for the manufacture of a medicament for treating or preventing a condition selected from among subsequent brain deficits or resulting from deviation surgery. cardiac and grafts, stroke, cerebral ischaemia, spinal cord trauma, cephalic trauma, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, AIDS-induced dementia, perinatal hypoxia, hypoxia (such as the conditions caused by strangulation, surgery, smoke inhalation, suffocation, drowning, airway obstruction, electrocution or overdose f of drugs or alcohol), cardiac arrest, neuronal injury, hypoglycemic, tolerance to opiates, withdrawal syndrome (such as the one produced for 15 alcoholism and for drug addiction, including addiction to apláceos, cocaine, and nicotin a) idiopathic and drug-induced Parkinson's disease or cerebral edema, muscle spasms, migraines, urinary incisions, psychosis, seizures, chronic or acute pain, ocular lesions, retinopathy, retinal neuropathy, tinnitus, anxiety, emesis and tardive dyskinesia, 20 in a mammal.